var docs;if (!docs) docs =[]; docs["28"]={"2802":"<p><b>Title</b> PenicillAMINE / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of PenicillAMINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of penicillamine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased. May consider spacing doses of penicillamine and antacid by 2 or more hours to reduce effect.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A study in 6 normal subjects showed a decrease in the absorption of penicillamine (approximately one-third) when coadministered with aluminum/magnesium hydroxide.<sup>1</sup> The mechanism of this interaction is unknown, but may be related to either a) the formation of a relatively unabsorbable chelate between the antacid and penicillamine; or b) decreased penicillamine stability at the higher pH caused by the antacid.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Osman MA, Patel RB, Schuna A, et al, “Reduction in Oral Penicillamine Absorption by Food, Antacid, and Ferrous Sulfate,” <i>Clin Pharmacol Ther</i>, 1983, 33(4):465-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6831825\">[PubMed 6831825]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2804":"<p><b>Title</b> Corticosteroids (Oral) / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the bioavailability of Corticosteroids (Oral). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider separating the doses of these agents by 2 or more hours to minimize the interaction (the effectiveness of this action in unknown). Monitor for decreased therapeutic effects of the oral corticosteroid. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p><b>Corticosteroids (Oral) Interacting Members</b> Budesonide (Systemic), Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Data regarding the effect of antacids on oral corticosteroids are inconsistent. Some patients have showed as much as a 40% decrease in prednisone bioavailability when coadministered with aluminum/magnesium hydroxide.<sup>1</sup> Dexamethasone bioavailability has been reported to be reduced as much as 75% when coadministered with magnesium trisilicate.<sup>2</sup> Oral prednisolone bioavailability has also been significantly affected, at times, when coadministered with magnesium trisilicate.<sup>3</sup> In contrast, not all data confirms these results.<sup>3,4,5</sup> The mechanism for these interactions is unknown, but may be related to adsorption of the corticosteroid onto the antacid. The impact of pH changes induced by the antacid is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Uribe M, Casian C, Rojas S, et al, “Decreased Bioavailability of Prednisone Due to Antacids in Patients With Chronic Active Liver Disease and in Healthy Volunteers,” <i>Gastroenterology</i>, 1981, 80(4):661-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7202937\">[PubMed 7202937]</a></p>\n<p>2. Naggar VF, Khalil SA, and Gouda MW, “Effect of Concomitant Administration of Magnesium Trisilicate on GI Absorption of Dexamethasone in Humans,” <i>J Pharm Sci</i>, 1978, 67(7):1029-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=207854\">[PubMed 207854]</a></p>\n<p>3. Lee DA, Taylor GM, Walker JG, et al, “The Effect of Concurrent Administration of Antacids on Prednisolone Absorption,” <i>Br J Clin Pharmacol</i>, 1979, 8(1):92-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=552304\">[PubMed 552304]</a></p>\n<p>4. Tanner AR, Caffin JA, Halliday JW, et al, “Concurrent Administration of Antacids and Prednisone: Effect on Serum Levels of Prednisolone,” <i>Br J Clin Pharmacol</i>, 1979, 7(4):397-400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=444359\">[PubMed 444359]</a></p>\n<p>5. Albin H, Vincon G, Demotes-Mainard F, et al, “Effects of Aluminum Phosphate on the Bioavailability of Cimetidine and Prednisolone,” <i>Eur J Clin Pharmacol</i>, 1984, 26(2):271-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6723769\">[PubMed 6723769]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2806":"<p><b>Title</b> Amphetamines / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the excretion of Amphetamines. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of amphetamines if an antacid is initiated/dose increased, or decreased effects if an antacid is discontinued/dose decreased.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Alkalinizing the urine with sodium bicarbonate can dramatically decrease the excretion of amphetamine; possibly to as little as 3% of original dose over 16 hours.<sup>1</sup> The effect of other antacids is probably less. Amphetamines exist in a more readily absorbed nonionized form in alkaline urine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Beckett AH, Rowland M, and Turner P, “Influence of pH on Excretion of Amphetamine,” <i>Lancet</i>, 1965, 1(7380):303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14247879\">[PubMed 14247879]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2808":"<p><b>Title</b> QuiNIDine / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is limited to ingestion of antacid products/doses that are capable of alkalinizing the urine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antacids may decrease the excretion of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for toxic effects of quinidine if antacid (in sufficient doses to alkalinize the urine) is initiated/dose increased, or decreased effects if a similarly dosed antacid is discontinued/dose decreased.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate*<br><b>Exception</b> Aluminum Hydroxide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The urinary excretion of quinidine was decreased by approximately 50% in 4 normal subjects due to alkalinizing the urine with sodium bicarbonate.<sup>1</sup> Quinidine appears to be unaffected by coadministration with aluminum hydroxide.<sup>2,3</sup> In alkaline urine (such as caused by sodium bicarbonate) quinidine is present more in the nonionized, absorbable, form. Other antacids may have a similar effect on quinidine, but the extent of the interaction would likely be less due to typically lesser effects on urine pH. Evidence of clinical effects caused by these interactions appears to be lacking.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gerhardt RE, Knouss RF, Thyrum PT, et al, “Quinidine Excretion in Aciduria and Alkaluria,” <i>Ann Intern Med</i>, 1969, 71(5):927-33. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5360313\">[PubMed 5360313]</a></p>\n<p>2. Ace LN, Jaffe JM, and Kunka RL, “Effect of Food and Antacid on Quinidine Bioavailability,” <i>Biopharm Drug Disopos</i>, 1983, 4(2):183-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6882885\">[PubMed 6882885]</a></p>\n<p>3. Mauro VF, Mauro LS, Fraker TD, et al, “Effect of Aluminum Hydroxide Gel on Quinidine Gluconate Absorption,” <i>DICP</i>, 1990, 24(3):252-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2316233\">[PubMed 2316233]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2809":"<p><b>Title</b> RifAMPin / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only of potential concern with oral rifampin. No interaction is expected with intravenous administration of rifampin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of RifAMPin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action is required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 14 healthy volunteers, the AUC and maximum serum concentration (Cmax) of rifampin (600 mg single oral dose) were unchanged when administered with aluminum/magnesium hydroxide (Mylanta 30 mL) given 9 hours before, at the time of dose, after meals, and at bedtime after dose.<sup>1</sup> In another study of 45 patients with pulmonary tuberculosis, the mean rifampin serum concentrations observed at 2 hours, 3 hours, and 4 hours after rifampin (10-12 mg/kg single oral dose), were similar in patients who received no antacid compared with patients who received aluminum hydroxide (1,220 mg) or aluminum hydroxide/magnesium trisilicate (1,250 mg/2,500 mg) with their rifampin therapy.<sup>2</sup> The authors do report that more patients failed to reach a Cmax of 6.5 mcg/mL or greater in the aluminum hydroxide group compared with the groups who received no antacid or aluminum hydroxide/magnesium trisilicate (8 vs 1 vs 0 patients; <i>P</i> = 0.001).<sup>2</sup> <br><br>US and Canadian labeling for rifampin products states that because coadministration of rifampin with antacids may reduce rifampin absorption, rifampin should be given 1 hour prior to any antacid.<sup>3,4,5,6,7</sup> The effect of this dose separation has not been evaluated in a clinical study.<br><br>The mechanism of this potential interaction has not been investigated, but reduced absorption caused by elevated gastric pH or chelation and/or adsorption of rifampin onto antacids has been proposed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. <i>Chest</i>. 1999;115(1):12-18. [PMID 9925057]</p>\n<p>2. Gupta PR, Mehta YR, Gupta ML, Sharma TN, Jain D, Gupta RB. Rifampin-aluminium antacid interaction. <i>J Assoc Physicians India</i>. 1988;36(6):363-364. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3182711\">[PubMed 3182711]</a></p>\n<p>3. <i>Rifater</i> (rifampin/isoniazid/pyrazinamide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013.</p>\n<p>4. <i>Rifadin</i> (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; February 2013.</p>\n<p>5. <i>Rifamate</i> (rifampin/isoniazid) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2013.</p>\n<p>6. <i>Rifadin</i> (rifampin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; July 2010.</p>\n<p>7. <i>Rifater</i> (rifampin/isoniazid/pyrazinamide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; March 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2810":"<p><b>Title</b> Sodium Polystyrene Sulfonate / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction may be avoided with rectal administration of Sodium Polystyrene Sulfonate.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> To minimize this interaction, consider: a) separating the doses of sodium polystyrene sulfonate (SPS) and antacids by 2 or more hours; b) administering SPS rectally; or c) choosing an alternative acid reducing agent (e.g. H2-antagonist). Monitor for metabolic alkalosis and attenuation of SPS effects if concomitant therapy cannot be avoided. Avoid magnesium hydroxide.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate*, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate<br><b>Exception</b> Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum bicarbonate concentrations were increased in 11 patients who received concomitant antacids (containing magnesium or calcium) and sodium polystyrene sulfonate.<sup>1</sup> Additional reports support these findings.<sup>2,3,4</sup> In one case, the drug combination (90 g of sodium polystyrene sulfonate with 90 mL of a magnesium hydroxide mixture) was used to reverse metabolic acidosis.<sup>3</sup> <br><br>The exact mechanism of this interaction is unknown. Sodium polystyrene sulfonate binds magnesium and calcium ions, and may thereby prevent binding and neutralizing of bicarbonate ions in the small intestine. Additionally, the binding of SPS to cations from antacid preparations may attenuate the therapeutic effects of SPS. Prescribing information for SPS highlights this risk of alkalosis with cation-donating antacids, but does not give specific recommendations for action.<sup>5</sup> It does recommend avoidance of magnesium hydroxide.<sup>5</sup> Strategies to reduce this interaction in the event that concomitant treatment cannot be avoided include rectal administration of SPS and separating the doses of the SPS and the antacid.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schroeder ET, “Alkalosis Resulting From Combined Administration of a 'Nonsystemic' Antacid and a Cation-Exchange Resin,” <i>Gastroenterology</i>, 1969, 56(5):868-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5782298\">[PubMed 5782298]</a></p>\n<p>2. Fernandez PC and Kovnat PJ, “Metabolic Acidosis Reversed by the Combination of Magnesium and a Cation-Exchange Resin,” <i>N Engl J Med</i>, 1972, 286(1):23-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5006921\">[PubMed 5006921]</a></p>\n<p>3. Ziessman HA, “Alkalosis and Seizure Due to a Cation-Exchange Resin and Magnesium Hydroxide,” <i>South Med J</i>, 1976, 69(4):497-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=817399\">[PubMed 817399]</a></p>\n<p>4. Madias NE and Levey AS, “Metabolic Alkalosis due to Absorption of ”Nonabsorbable“ Antacids,” <i>Am J Med</i>, 1983, 74(1):155-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6849324\">[PubMed 6849324]</a></p>\n<p>5. Prescribing information. Kayexalate (sodium polystyrene sulfonate). Bridewater, NJ: Sanofi-Aventis U.S. LLC, September 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2812":"<p><b>Title</b> Theophylline Derivatives / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Theophylline Derivatives. <b>Severity</b> Minor <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide*, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Dyphylline, Theophylline*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Data fail to demonstrate any significant effect of antacids (specifically, aluminum/magnesium hydroxide) on theophylline pharmacokinetics.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Arnold LA, Spurbeck GH, Shelver WH, et al, “Effect of an Antacid on Gastrointestinal Absorption of Theophylline,” <i>Am J Hosp Pharm</i>, 1979, 36(8):1059-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=484565\">[PubMed 484565]</a></p>\n<p>2. Reed RC and Schwartz HJ, “Lack of Influence of an Intensive Antacid Regimen on Theophylline Bioavailability,” <i>J Pharmacokinet Biopharm</i>, 1984, 12(3):315-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502473\">[PubMed 6502473]</a></p>\n<p>3. Darzentas LJ, Stewart RB, Curry SH, et al, “Effect of Antacid on Bioavailability of a Sustained-Release Theophylline Preparation,” <i>Drug Intell Clin Pharm</i>, 1983, 17(7-8):555-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6872853\">[PubMed 6872853]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2818":"<p><b>Title</b> Methenamine / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is primarily limited to antacid use at doses large enough to cause alkalinization of the urine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may diminish the therapeutic effect of Methenamine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider using an agent other than methenamine, or discontinue use of the antacid. Sodium bicarbonate is of most concern. Other antacids are likely of concern only if taken in large doses. Spacing the doses may help minimize the effects; however, the success of this action is unknown. Monitor for decreased therapeutic effects of methenamine if used concomitant with antacids.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Methenamine requires a urinary pH &lt;6 in order to be hydrolyzed into formaldehyde, and thus provide antiseptic activity. Agents which alkalinize the urine (eg, carbonic anhydrase inhibitors, sodium bicarbonate, and some other antacids if taken in sufficient quantities) can render methenamine ineffective.<sup>1,2</sup> Product labeling states that restriction of such agents is desirable.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Urex (methenamine) [prescribing information]. Wytheville, VA: Vatring Pharmaceuticals, Inc.; December 2006.</p>\n<p>2. Hiprex (methenamine) [prescribing information]. Bridgewater, NJ: Aventis Pharmaceuticals Inc.; February 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2821":"<p><b>Title</b> Trientine / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the absorption of Trientine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate trientine dosing from those of other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> The manufacturer of Syprine® (trientine) states that it should be taken “at least one hour apart from any other drug, food, or milk. This permits maximum absorption and reduces the likelihood of inactivation of the drug by metal binding in the gastrointestinal tract.”<sup>1</sup> It would seem especially important to heed this information when administering antacids.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Syprine (trientine). West Point, PA: Merck &amp; Co, Inc, May 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2822":"<p><b>Title</b> Calcium Salts / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of calcium if a thiazide diuretic is initiated or the dose is increased.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate*, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide*, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide*, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case reports describe hypercalcemia, and signs and symptoms of the milk-alkali syndrome (including dizziness, weakness, hypercalcemia, metabolic and alkalosis with respiratory compensation), developing in conjunction with concomitant use of thiazide diuretics and calcium supplementation.<sup>1,2,3,4</sup> Thiazide diuretics inhibit the excretion of calcium, as well as bicarbonate. As such, calcium supplementation can result in the noted adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Drinka PJ and Nolten WE, “Hazards of Treating Osteoporosis and Hypertension Concurrently With Calcium, Vitamin D, and Distal Diuretics,” <i>J Am Geriat Soc</i>, 1984, 32(5):405-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6715769\">[PubMed 6715769]</a></p>\n<p>2. Hakim R, Tolis G, Goltzman D, et al, “Severe Hypercalcemia Associated With Hydrochlorothiazide and Calcium Carbonate Therapy,” <i>Can Med Assoc J</i>, 1979, 121(5):591-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=497950\">[PubMed 497950]</a></p>\n<p>3. Gora ML, Seth SK, Bay WH, et al, “Milk-Alkali Syndrome Associated With Use of Cholorothiazide and Calcium Carbonate,” <i>Clin Pharm</i>, 1989, 8(3):227-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27006898\">[PubMed 27006898]</a></p>\n<p>4. Parfitt AM, “Chlorothiazide-Induced Hypercalcemia in Juvenile Osteoporosis and Hyperparathyroidism,” <i>N Engl J Med</i>, 1969, 281(2):55-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5305802\">[PubMed 5305802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2823":"<p><b>Title</b> Cardiac Glycosides / Calcium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of cardiac glycosides (especially cardiac arrhythmias) if a calcium product (especially intravenous, high dose, or rapid administration) is initiated or the dose is increased.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride*, Calcium Citrate, Calcium Glubionate, Calcium Gluconate*, Calcium Lactate, Polycarbophil</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> One case report describes an 81-year-old female who was stabilized on digoxin therapy for 1 year.<sup>1</sup> She was admitted to the hospital following a syncopal episode and found to have a serum calcium level of 12 mg/dL (normal 8.8-10 mg/dL) and a digoxin level of 1.5 ng/mL (normal 0.5-2 ng/mL). Several sinus pauses (2 to 5 seconds) were seen during her first 12 hours of hospital admission. Serum calcium was corrected with diuretics and hydration, digoxin was discontinued, and no further syncope or arrhythmias recurred.<sup>1</sup> Other cases of calcium administration or hypercalcemia resulting in digitalis toxicity have been reported, but causal relationships were not firmly established.<sup>2,3</sup> In one case, a patient receiving digoxin (0.25 mg twice daily) was hypercalcemic (11 mg/dL) and experienced ventricular fibrillation after administration of succinylcholine.<sup>2</sup> However, it is unclear what role digoxin alone may have played as the patient was receiving a large dose of digoxin and began therapy with quinidine, a drug known to increased digoxin levels,<sup>4,5</sup> 2 days prior to the event. No digoxin levels were reported. A final report describes 2 patients receiving digitoxin who experienced sudden cardiac death after intravenous calcium administration, but no digitoxin serum levels, EKGs, or serum potassium levels are described.<sup>3</sup> <br><br>Cardiac glycosides inhibit the sodium-potassium ATP pump (Na<sup>+</sup>/K<sup>+</sup>-ATPase) and deplete intracellular sodium. This inhibits the calcium-sodium antiporter (Ca<sup>2+</sup>/Na<sup>+</sup> pump) and ultimately leads to increases in intracellular calcium. Since both cardiac glycosides and excess calcium (i.e., hypercalcemia) decrease the cardiac excitation threshold, shorten the effective refractory period, and increase the refractoriness of the AV node, the combination may increase the risk for cardiac toxicities.<sup>1</sup> However, the scarcity of interaction reports make the clinical significance uncertain. Animal data indicate that a significant digoxin-calcium interaction only occurs at high concentrations of calcium, which may not be achieved with routine use of calcium salts .<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vella A, Gerber TC, Hayes DL, Reeder GS. Digoxin, hypercalcaemia, and cardiac conduction. <i>Postgrad Med J</i>. 1999;75(887):554-556. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616693\">[PubMed 10616693]</a></p>\n<p>2. Smith RB, Petruscak J. Succinylcholine, digitalis, and hypercalcemia: a case report. <i>Anesth Analg</i>. 1972;51(2):202-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5062119\">[PubMed 5062119]</a></p>\n<p>3. Bower JO, Mengle HA. The additive effect of calcium and digitalis. A warning with a report of two deaths. <i>JAMA</i>. 1936;106(14):1151-1153.</p>\n<p>4. Leahey EB Jr, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT Jr. Interaction between quinidine and digoxin. <i>JAMA</i>. 1978;240(6):533-534. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=671662\">[PubMed 671662]</a></p>\n<p>5. Ejvinsson G. Effect of quinidine on plasma concentrations of digoxin. <i>Br Med J</i>. 1978;1(6108):279-280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=620306\">[PubMed 620306]</a> </p>\n<p>6. Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. <i>Am Heart J</i>. 1970;79(4):499-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5418023\">[PubMed 5418023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2824":"<p><b>Title</b> Calcium Channel Blockers / Calcium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects (see Discussion) of calcium channel blockers if a calcium supplement is initiated/dose increased, or increased effects if a calcium supplement is discontinued/dose decreased.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil*</p>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride*, Calcium Citrate, Calcium Glubionate, Calcium Gluconate*, Calcium Lactate, Polycarbophil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Various reports describe decreased therapeutic and/or toxic effects (antihypertensive and antiarrhythmic) of verapamil and nifedipine when administered with calcium supplements. The hypotensive effects and negative inotropic effects (verapamil) are usually inhibited without affecting the antiarrhythmic (verapamil) or anti-ischemic (nifedipine) effects.<sup>1,2,3,4,5</sup> This can be used advantageously (eg, IV calcium pretreatment for an atrial fibrillation patient (with a rapid ventricular response, and a risk for hypertension) who is to receive verapamil). However, a case report describes the redevelopment of atrial fibrillation in a patient controlled on verapamil within a week of starting daily doses of calcium adipate (1.2 g) and calciferol (3000 IU).<sup>6</sup> It is presumed that increasing the extracellular calcium concentration may oppose the effects of the calcium channel blocker.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Salerno DM, Anderson B, Sharkey PH, et al, “Intravenous Verapamil for Treatment of Multifocal Atrial Tachycardia With and Without Calcium Pretreatment,” <i>Ann Intern Med</i>, 1987, 107(5):623-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3662276\">[PubMed 3662276]</a></p>\n<p>2. Haft JI and Habbab MA, “Treatment of Atrial Arrhythmias. Effectiveness of Verapamil When Preceded by Calcium Infusion,” <i>Arch Intern Med</i>, 1986, 146(6):1085-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3718093\">[PubMed 3718093]</a></p>\n<p>3. Schoen MD, Parker RB, Hoon TJ, et al, “Evaluation of the Pharmacokinetics and Electrocardiographic Effects of Intravenous Verapamil With Intravenous Calcium Chloride Pretreatment in Normal Subjects,” <i>Am J Cardiol</i>, 1991, 67(4):300-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1990794\">[PubMed 1990794]</a></p>\n<p>4. O’Quinn SV, et al, “Influence of Calcium on the Hemodynamic and Anti-ischemic Effects of Nifedipine Observed During Treadmill Exercise Testing,” <i>Pharmacotherapy</i>, 1990, 10:247 (abstract).</p>\n<p>5. Wohns DH, Patterson JH, Clarke S, et al, “Influence of Calcium Administration on the Short-term Hemodynamic and the Anti-ischemic Effects of Nifedipine,” <i>J Am Coll Cardiol</i>, 1991, 18(4):1070-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1894852\">[PubMed 1894852]</a></p>\n<p>6. Bar-Or D and Gasiel Y, “Calcium and Calciferol Antagonize Effect of Verapamil in Atrial Fibrillation,” <i>Br Med J</i>, 1981, 282(6276):1585-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6786574\">[PubMed 6786574]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2825":"<p><b>Title</b> Thyroid Products / Calcium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Salts may diminish the therapeutic effect of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate*, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine*, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> TSH significantly increased and both free and total T4 decreased with concurrent administration of calcium carbonate (1200 mg/d of elemental calcium) in a prospective cohort study of 20 patients previously stabilized on levothyroxine.<sup>1</sup> After discontinuation of calcium carbonate, TSH and T4 value returned towards baseline values. Similarly, a study in 8 healthy volunteers reported a 20-25% decrease in levothyroxine absorption associated with concurrent ingestion of calcium carbonate, calcium citrate, and calcium acetate (500 mg of elemental calcium each).<sup>2</sup> Several case reports also describe increases in TSH values and/or decreases in T4 associated with concurrent use of calcium carbonate in patients previously stabilized on levothyroxine.<sup>3,4,5,6,7</sup> In a database analysis, median serum TSH concentrations were 0.27 mIU/L greater in the 6 months following calcium initiation compared to the year prior in 450 patients receiving stable levothyroxine doses.<sup>8</sup> TSH concentrations following calcium initiation increased by at least 5 mIU/L in 4.4% of patients, and decreased by at least 5 mIU/L in 3.3% of patients.<br><br>The mechanism of this interaction appears to be due to adsorption of levothyroxine to calcium in the GI tract. An in vitro study confirmed that in acidic conditions, levothyroxine does adsorb to calcium carbonate.<sup>1</sup> Reports that separation of calcium carbonate and levothyroxine administration successfully avoids the interaction<sup>5</sup> lend further support to this as the mechanism. The degree to which other thyroid products and/or other calcium products are at risk for this interaction is unclear. In contrast to one study of healthy volunteers that found a similarly significant interaction with calcium carbonate, calcium citrate, and calcium acetate,<sup>2</sup> one analysis has concluded that calcium acetate may be associated with a lower interaction risk than calcium carbonate.<sup>9</sup> In a study of 67 hemodialysis patients receiving levothyroxine together with a phosphate binder, those patients receiving calcium carbonate had significantly higher TSH values than those patients receiving calcium acetate.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Singh N, Singh PN, Hershman JM, “Effect of Calcium Carbonate on the Absorption of Levothyroxine,” <i>JAMA</i>, 2000;283:2822-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10838651\">[PubMed 10838651]</a></p>\n<p>2. Zamfirescu I, Carlson HE, “Absorption of Levothyroxine when Coadministered with Various Calcium Formulations,” <i>Thyroid</i>, 2011, 21(5):483-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21595516\">[PubMed 21595516]</a></p>\n<p>3. Singh N, Weisler SL, Hershman JM, “The Acute Effect of Calcium Carbonate on the Intestinal Absorption of Levothyroxine,” <i>Thyroid</i>, 2001;11:967-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11716045\">[PubMed 11716045]</a></p>\n<p>4. Mazokopakis EE, Giannakopoulos TG, Starakis IK, “Interaction Between Levothyroxine and Calcium Carbonate,” <i>Can Fam Physician</i>, 2008, 54(1):39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18208953\">[PubMed 18208953]</a></p>\n<p>5. Csako G, McGriff NJ, Rotman-Pikielny P, et al, “Exaggerated Levothyroxine Malabsorption Due to Calcium Carbonate Supplementation in Gastrointestinal Disorders,” <i>Ann Pharmacother</i>, 2001, 35(12):1578-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11793625\">[PubMed 11793625]</a></p>\n<p>6. Butner LE, Fulco PP, Feldman G, “Calcium Carbonate-Induced Hypothyroidism,” <i>Ann Intern Med</i>, 2000, 132(7):595. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10744606\">[PubMed 10744606]</a></p>\n<p>7. Schneyer CR, “Calcium Carbonate and Reduction of Levothyroxine Efficacy,” <i>JAMA</i>, 1998, 279(10):750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9508149\">[PubMed 9508149]</a></p>\n<p>8. A Irving S, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS) [published online July 17, 2014]. <i>Clin Endocrinol (Oxf)</i>. doi:10.1111/cen.12559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25040647\">[PubMed 25040647]</a></p>\n<p>9. Diskin CJ, Stokes TJ, Dansby LM, et al, “Effect of Phosphate Binders Upon TSH and L-Thyroxine Dose in Patients on Thyroid Replacement,” <i>Int Urol Nephrol</i>, 2007;39(2):599-602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17216296\">[PubMed 17216296]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2827":"<p><b>Title</b> DOBUTamine / Calcium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Calcium Salts may diminish the therapeutic effect of DOBUTamine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of dobutamine (specifically cardiac output) if a calcium supplement (especially IV) is initiated/dose increased.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride*, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A study in 22 patients (status post coronary bypass surgery) receiving dobutamine (2.5-5 mcg/kg/min) experienced a 30% reduction in cardiac output with concomitant administration of calcium chloride by continuous infusion (1 mg/kg/min, subsequently reduced to 0.25 mg/kg/min).<sup>1</sup> The patients in the study had a normal cardiac output prior to calcium administration. Milrinone was not affected by the calcium administration, and thus might be a lower risk alternative to dobutamine. The mechanism of this interaction is unknown. The authors of the report suggest that calcium may interfere with signal transduction through the beta-adrenergic receptor complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Butterworth JF 4th, Zaloga GP, Prielipp RC, Tucker WY Jr, Royster RL. Calcium inhibits the cardiac stimulating properties of dobutamine but not of amrinone. <i>Chest</i>. 1992;101(1):174-180. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1729065\">[PubMed 1729065]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2828":"<p><b>Title</b> Aminoglycosides / Magnesium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Magnesium Salts may enhance the neuromuscular-blocking effect of Aminoglycosides. Primarily of concern in patients with elevated serum magnesium concentrations. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for negative respiratory effects if an aminoglycoside is used in a patient who has an elevated serum magnesium concentration, or in a patient in whom a magnesium supplement is initiated or dose is increased.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n <p><b>Magnesium Salts Interacting Members</b> Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Glucoheptonate, Magnesium Glycerophosphate, Magnesium L-lactate, Magnesium Sulfate*, Magnesium Trisilicate<br><b>Exceptions</b> Almagate, Magnesium Citrate, Magnesium Gluconate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium Oxide, Magnesium Salicylate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. A baby girl was born with muscle weakness and a serum magnesium concentration of 4.3 mg/dL (mother received magnesium sulfate prior to delivery). The baby was placed on ampicillin and gentamicin (2.5 mg/kg every 12 hours). Following the second dose of gentamicin the baby stopped breathing and required intubation. No additional gentamicin was administered, and the baby improved.<sup>1</sup> Both aminoglycosides and magnesium possess neuromuscular blocking activity. Their effects appeared to be additive in this case report.</p> \n<p><b>Footnotes</b> </p>\n<p>1. L’Hommedieu CS, Nicholas D, Armes DA, et al, “Potentiation of Magnesium Sulfate-Induced Neuromuscular Weakness by Gentamicin, Tobramycin, and Amikacin,” <i>J Pediatr</i>, 1983, 102(4):629-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6834204\">[PubMed 6834204]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2832":"<p><b>Title</b> Amantadine / Triamterene</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Triamterene may enhance the adverse/toxic effect of Amantadine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for toxic effects of amantadine (eg, agitation, ataxia, hallucinations) if triamterene is initiated or the dose is increased. Patients with reduced renal function might be at particular risk for this interaction.</p> \n<p><b>Discussion</b> Agitation, ataxia, and hallucinations developed in a 61-year old patient on amantadine within a week of initiating hydrochlorothiazide/triamterene therapy.<sup>1</sup> Symptoms abated following discontinuation of both agents. Amantadine was restarted without incident, but serum amantadine concentrations increased from 156 to 243 ng/mL within 7 days of reinitiating hydrochlorothiazide/triamterene therapy. The mechanism of this interaction is unknown and, therefore, the ability to specifically link the interaction to either triamterene or hydrochlorothiazide is hindered.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wilson TW and Rajput AH, “Amantadine-Dyazide Interaction,” <i>Can Med Assoc J</i>, 1983, 129(9):974-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6671185\">[PubMed 6671185]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2833":"<p><b>Title</b> Amantadine / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Amantadine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for toxic effects of amantadine (eg, agitation, ataxia, hallucinations) if a thiazide diuretic is initiated or the dose is increased. Patients with reduced renal function might be at particular risk for this interaction.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Agitation, ataxia, and hallucinations developed in a 61-year-old patient on amantadine within a week of initiating hydrochlorothiazide/triamterene therapy.<sup>1</sup> Symptoms abated following discontinuation of both agents. Amantadine was restarted without incident, but serum amantadine concentrations increased from 156 to 243 ng/mL within 7 days of reinitiating hydrochlorothiazide/triamterene therapy. Both the mechanism of this interaction and whether it is primarily due to triamterene or hydrochlorothiazide are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wilson TW, Rajput AH. Amantadine-dyazide interaction. <i>Can Med Assoc J</i>. 1983;129(9):974-975. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6671185\">[PubMed 6671185]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2835":"<p><b>Title</b> Aminoglycosides / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of aminoglycosides (i.e., ototoxicity or nephrotoxicity) if a loop diuretic is initiated or the dose is increased. This is probably of most concern if the diuretic is administered in high doses for extended periods of time. The manufacturer labeling for some loop diuretics recommend avoiding concomitant use with aminoglycosides except in life-threatening situations.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Data are conflicting regarding the influence of loop diuretics on the incidence of aminoglycoside-associated nephro- or ototoxicity. Case reports and clinical studies have reported associations between concurrent loop diuretics and aminoglycosides and nephrotoxicity and/or ototoxicity.<sup>1,2,3</sup> Similarly, animal studies have also reported associations between nephrotoxicity/ototoxicity and concurrent use of a loop diuretic and an aminoglycoside.<sup>4,5</sup> One clinical study found an association between concurrent furosemide and aminoglycoside-associated nephrotoxicity in an analysis considering only these factors, but the association became not significant when controlling for other risk factors.<sup>6</sup> Several clinical studies have also reported no association between nephro- or ototoxicity and concurrent aminoglycosides and loop diuretics.<sup>7,8,9</sup><br><br>Higher loop diuretic doses, low serum albumin concentrations, and younger-aged patients have been identified as possible risk factors for loop diuretic toxicity.<sup>10,11</sup> Due to the possible increase in risk for ototoxicity, the prescribing information for several loop diuretics recommend avoiding concomitant use with aminoglycosides,<sup>12,13,14</sup> though some state that concomitant use may be employed in life-threatening conditions.<sup>12,13</sup><br><br>The mechanism(s) for this possible interaction is uncertain, but several possibly contributing factors have been identified. Furosemide has been shown to decrease aminoglycoside clearance,<sup>15,16</sup> alter aminoglycoside volume of distribution,<sup>16</sup> increase accumulation of aminoglycosides in renal tissues,<sup>17</sup> enhance aminoglycoside-induced cellular changes in proximal tubular cells,<sup>18</sup> and to decrease overall glomerular filtration rate.<sup>15</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prins JM, Weverling GJ, de Blok K, et al, “Validation and Nephrotoxicity of a Simplified Once-Daily Aminoglycoside Dosing Schedule and Guidelines for Monitoring Therapy,” <i>Antimicrob Agents Chemother</i>, 1996, 40:2494-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8913452\">[PubMed 8913452]</a></p>\n<p>2. Leehey DJ, Braun BI, Tholl DA, et al, “Can Pharmacokinetic Dosing Decrease Nephrotoxicity Associated with Aminoglycoside Therapy,” <i>J Am Soc Nephrol</i>, 1993, 4:81-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8400072\">[PubMed 8400072]</a></p>\n<p>3. Bates DE, Beaumont SJ, Baylis BW, “Ototoxicity Induced by Gentamicin and Furosemide,” <i>Ann Pharmacother</i>, 2002, 36:446-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11895059\">[PubMed 11895059]</a></p>\n<p>4. Adelman RD, Spangler WL, Beasom F, et al, “Furosemide Enhancement of Experimental Gentamicin Nephrotoxicity: Comparison of Functional and Morphological Changes with Activities of Urinary Enzymes,” <i>J Infect Dis</i>, 1979, 140(3):342-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=501148\">[PubMed 501148]</a></p>\n<p>5. Brummett RE, Bendrick T, and Himes D, “Comparative Ototoxicity of Bumetanide and Furosemide When Used in Combination with Kanamycin,” <i>J Clin Pharmacol</i>, 1981, 21(11-12 Pt 2):628-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7338574\">[PubMed 7338574]</a></p>\n<p>6. Bertino JS, Jr., Booker LA, Franck PA, et al, “Incidence of and Significant Risk Factors for Aminoglycoside-Associated Nephrotoxicity in Patients Dosed by Using Individualized Pharmacokinetic Monitoring,” <i>J Infect Dis</i>, 1993, 167:173-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8418164\">[PubMed 8418164]</a></p>\n<p>7. Smith CR and Lietman PS, “Effect of Furosemide on Aminoglycoside-Induced Nephrotoxicity and Auditory Toxicity in Humans,” <i>Antimicrob Agents Chemother</i>, 1983, 23(1):133-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6830203\">[PubMed 6830203]</a></p>\n<p>8. Moore RD, Smith CR, Lipsky JJ, et al, “Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides,” <i>Ann Intern Med</i>, 1984, 100:352-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6364908\">[PubMed 6364908]</a></p>\n<p>9. Schentag JJ, Cerra FB, Plaut ME, “Clinical and Pharmacokinetic Characteristics of Aminoglycoside Nephrotoxicity in 201 Critically Ill Patients,” <i>Antimicrob Agents Chemother</i>, 1982, 21:721-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7103453\">[PubMed 7103453]</a></p>\n<p>10. Whitworth C, Morris C, Scott V, et al, “Dose-Response Relationships for Furosemide Ototoxicity in Rat,” <i>Hear Res</i>, 1993, 71:202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8113137\">[PubMed 8113137]</a></p>\n<p>11. Rybak LP, Whitworth C, Scott V, et al, “Ototoxicity of Furosemide During Development,” <i>Laryngoscope</i>, 1991, 101:1167-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1943418\">[PubMed 1943418]</a></p>\n<p>12. Prescribing information. Lasix (furosemide). Bridgewater, NJ: sanofi-aventis U.S. LLC, January 2011.</p>\n<p>13. Prescribing information. Bumetanide. Bedford, OH: Bedford Laboratories, February 2010.</p>\n<p>14. Prescribing information. Edecrin (ethacrynic acid). Whithouse Station, NJ: Merck &amp; Co., Inc., February 2005.</p>\n<p>15. Lawson DH, Tilstone WJ, Gray JM, et al, “Effect of Furosemide on the Pharmacokinetics of Gentamicin in Patients,” <i>J Clin Pharmacol</i>, 1982, 22(5-6):254-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7107971\">[PubMed 7107971]</a></p>\n<p>16. Kaka JS, Lyman C, and Kilarski DJ, “Tobramycin-Furosemide Interaction,” <i>Drug Intell Clin Pharm</i>, 1984, 18(3):235-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6697885\">[PubMed 6697885]</a></p>\n<p>17. Nakahama H, Fukuhara Y, Orita Y, et al, “Furosemide Accelerates Gentamicin Accumulation in Cultured Renal Cells (LLC-PK1 Cells),” <i>Nephron</i>, 1989, 53:138-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2812167\">[PubMed 2812167]</a></p>\n<p>18. Nakahama H, Shin S, Moriyama T, “Enhancement of Gentamicin-Induced Inhibition of Phosphatidylinositol Hydrolysis in Rabbit Renal Proximal Tubular Brush-Border Membrane by Furosemide,” <i>Ren Fail</i>, 1989, 11(2-3):105-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2623196\">[PubMed 2623196]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2836":"<p><b>Title</b> Aminoglycosides / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased nephrotoxic effects of aminoglycosides if a nonsteroidal anti-inflammatory agents is initiated or the dose is increased. This is of particular concern in preterm infants.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin*, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Both gentamicin and amikacin peak and trough serum concentrations increased significantly within 24 hours of starting indomethacin therapy in preterm infants. All patients had received an aminoglycoside for at least 3 days prior to indomethacin initiation. The respective increases in serum peak and trough concentrations were 32% and 48% for gentamicin, and 17% and 28% for amikacin.<sup>1</sup> Another study found no effect of indomethacin on gentamicin clearance in preterm infants.<sup>2</sup> The ability of indomethacin to reduce renal filtration may account for the changes in aminoglycoside clearance; however, the mechanism for the interaction is yet undefined. The effect of other nonsteroidal anti-inflammatory agents on other aminoglycosides is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zarfin Y, Koren G, Maresky D, et al, “Possible Indomethacin-Aminoglycoside Interaction in Preterm Infants,” <i>J Pediatr</i>, 1985, 106(3):511-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3973790\">[PubMed 3973790]</a></p>\n<p>2. Grylack LJ and Scanlon JW, “Interaction of Indomethacin and Gentamicin in Preterm Newborns,” <i>Pediatr Res</i>, 1988, 23:409A.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2837":"<p><b>Title</b> Neuromuscular-Blocking Agents / Aminoglycosides</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of neuromuscular-blocking agents (NMB), specifically respiratory depression, if an aminoglycoside is initiated/dose increased, or decreased effects if an aminoglycoside is discontinued/dose decreased.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin*, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin*, Streptomycin*, Tobramycin (Systemic)</p>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium*, Cisatracurium, Mivacurium, Pancuronium*, Rocuronium*, Succinylcholine*, Vecuronium*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Aminoglycosides possess some measure of neuromuscular-blocking activity which varies from one agent to another. When combined with neuromuscular-blocking agents, the respiratory depressant effects have been greater and longer.<sup>1,2,3,4,5,6</sup> The effects appear to manifest regardless of the route of aminoglycoside administration, including parenteral, oral, intraperitoneal, intraplural, and beneath skin flaps. The mechanism of these interactions is presumably due to an additive and/or synergistic effect on muscular tone. Aminoglycoside-induced neuromuscular-blockade may be dose-related.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Warner WA, Sanders E. Neuromuscular-blockade associated With gentamicin therapy. <i>JAMA</i>. 1971;215(7):1153-1154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4250687\">[PubMed 4250687]</a></p>\n<p>2. Levanen J, Nordman R. Complete respiratory paralysis caused by a large dose of streptomycin and its treatment with calcium chloride. <i>Ann Clin Res</i>. 1975;7(1):47-49. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1155911\">[PubMed 1155911]</a></p>\n<p>3. Holtzman JL. Gentamicin and neuromuscular blockade. <i>Ann Intern Med</i>. 1976;84(1):55-56 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1244797\">[PubMed 1244797]</a></p>\n<p>4. Boliston TA, Ashman R. Tobramycin neuromuscular blockade. <i>Anaesthesia</i>. 1978;33(6):552. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=686321\">[PubMed 686321]</a></p>\n<p>5. Jedeikin R, Dolgunski E, Kaplan R, et al. Prolongation of neuromuscular-blocking effect of vecuronium by antibiotics. <i>Anaesthesia</i>. 1987;42(8):858-860. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2889390\">[PubMed 2889390]</a></p>\n<p>6. Giala M, Sareyiannis C, Cortsaris N, et al. Possible interaction of pancuronium and tubocurarine with oral neomycin. <i>Anaesthesia</i>. 1982;37(7):776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7103026\">[PubMed 7103026]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2838":"<p><b>Title</b> Aminoglycosides / Penicillins</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Do not administer doses of aminoglycosides and penicillins simultaneously through the same IV administration line. Monitor serum aminoglycoside concentrations carefully. Delays in serum sample analysis, when determining aminoglycoside concentrations, may result in lower than actual results due to <i>in vitro</i> inactivation of the aminoglycoside. In addition, do not mix aminoglycosides and penicillins in the same <i>in vivo</i> infusion solution.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n <p><b>Penicillins Interacting Members</b> Amdinocillin, Flucloxacillin, Piperacillin*, Temocillin, Ticarcillin*<br><b>Exceptions</b> Amoxicillin, Ampicillin, Bacampicillin, Cloxacillin, Dicloxacillin, Nafcillin, Oxacillin, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Inactivation of aminoglycosides by extended spectrum penicillins, when mixed together in solution <i>in vitro</i>, is well documented.<sup>1,2,3,4</sup> The amino group on the aminoglycoside appears to form an inactive amide with the beta-lactam ring of the penicillin. A similar inactivation may occur in patients with renal dysfunction, decreasing aminoglycoside half-life to approximately one-half of the normal value, and making difficult the attempt to achieve therapeutic serum aminoglycoside concentrations.<sup>5,6,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. McLaughlin JE and Reeves DS, “Clinical and Laboratory Evidence for Inactivation of Gentamicin by Carbenicillin,” <i>Lancet</i>, 1971, 1(7693):261-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4100015\">[PubMed 4100015]</a></p>\n<p>2. Holt HA, Broughall JM, McCarthy M, et al, “Interactions Between Aminoglycoside Antibiotics and Carbenicillin or Ticarcillin,” <i>Infection</i>, 1976, 4(2):107-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7534\">[PubMed 7534]</a></p>\n<p>3. Davies M, Morgan JR, and Anand C, “Interactions of Carbenicillin and Ticarcillin With Gentamicin,” <i>Antimicrob Agents Chemother</i>, 1975, 7(4):431-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1147579\">[PubMed 1147579]</a></p>\n<p>4. Henderson JL, Polk RE, and Kline BJ, “<i>In vitro</i> Inactivation of Gentamicin, Tobramycin, and Netilmicin by Carbenicillin, Azlocillin, or Mezlocillin,” <i>Am J Hosp Pharm</i>, 1981, 38(8):1167-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6455916\">[PubMed 6455916]</a></p>\n<p>5. Weibert RT and Keane WF, “Carbenicillin-Gentamicin Interaction in Acute Renal Failure,” <i>Am J Hosp Pharm</i>, 1977, 34(10):1137-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=920745\">[PubMed 920745]</a></p>\n<p>6. Chow MS, Quintiliani R, and Nightingale CH, “<i>In vivo</i> Inactivation of Tobramycin by Ticarcillin. A Case Report,” <i>JAMA</i>, 1982, 247(5):658-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6798229\">[PubMed 6798229]</a></p>\n<p>7. Thompson MI, Russo ME, Saxon BJ, et al, “Gentamicin Inactivation by Piperacillin or Carbenicillin in Patients With End-Stage Renal Disease,” <i>Antimicrob Agents Chemother</i>, 1982, 21(2):268-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6462107\">[PubMed 6462107]</a></p>\n<p>8. Kradjan WA and Burger R, “<i>In vivo</i> Inactivation of Gentamicin by Carbenicillin and Ticarcillin,” <i>Arch Intern Med</i>, 1980, 140(12):1668-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7458498\">[PubMed 7458498]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2839":"<p><b>Title</b> Aminoglycosides / CISplatin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CISplatin may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased nephrotoxic effects of aminoglycosides if administered concomitantly with cisplatin. Monitor aminoglycoside serum concentrations carefully and adjust dosing accordingly.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> Significant reductions in renal function (as measured by creatinine clearance) have been reported in conjunction with concomitant therapy with cisplatin and an aminoglycoside (sometimes along with cephalothin).<sup>1,2,3</sup> Additional data demonstrated a doubling of the half-life of gentamicin when administered to pediatric patients also receiving cisplatin.<sup>4</sup> The mechanism of this interaction may be due to additive nephrotoxic effects of the individual agents, along with changes in the pharmacokinetic profile of the aminoglycoside.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Salem PA, Jabboury KW, and Khalil MF, “Severe Nephrotoxicity: A Probable Complication of Cis-Dichorodiammineplatinum (II) and Cephalothin-Gentamicin Therapy,” <i>Oncology</i>, 1982, 39(1):31-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7199128\">[PubMed 7199128]</a></p>\n<p>2. Haas A, Anderson L, and Lad T, “The Influence of Aminoglycosides on the Nephrotoxicity of Cis-Diamminedichloroplatinum in Cancer Patients,” <i>J Infect Dis</i>, 1983, 147(2):363. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6681828\">[PubMed 6681828]</a></p>\n<p>3. Dentino M, Luft FC, Yum MN, et al, “Long Term Effect of Cis-Diamminedichloride Platinum (CDDP) on Renal Function and Structure in Man,” <i>Cancer</i>, 1978, 41(4):1274-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=638991\">[PubMed 638991]</a></p>\n<p>4. Flombaum CD, “Hypomagnesemia Associated With Cisplatin Combination Chemotherapy,” <i>Arch Intern Med</i>, 1984, 144(12):2336-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6542341\">[PubMed 6542341]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2841":"<p><b>Title</b> Aminoglycosides / Vancomycin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vancomycin may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased nephrotoxic effects of aminoglycoside if administered concomitantly with vancomycin. Monitor aminoglycoside serum concentrations carefully and adjust dosing accordingly.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> Data indicates an increased incidence of renal dysfunction occurring with concomitant use of aminoglycosides and vancomycin compared to either agent used alone.<sup>1,2,3</sup> Another study showed a fivefold increase in urine alanine aminopeptidase (a marker of renal cell injury) in patients receiving concomitant aminoglycoside and vancomycin therapy compared with those receiving either agent alone.<sup>4</sup> The mechanism for these interactions are unknown, but may be related to additive and/or synergistic nephrotoxicity of the individual agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Farber BF and Moellering RC Jr, “Retrospective Study of the Toxicity of Preparations of Vancomycin From 1974-1981,” <i>Antimicrob Agents Chemother</i>, 1983, 23(1):138-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6219616\">[PubMed 6219616]</a></p>\n<p>2. Cimino MA, Rotstein C, Slaughter RL, et al, “Relationship of Serum Antibiotic Concentrations to Nephrotoxicity in Cancer Patients Receiving Concurrent Aminoglycoside and Vancomycin Therapy,” <i>Am J Med</i>, 1987, 83(6):1091-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3503577\">[PubMed 3503577]</a></p>\n<p>3. Pauly DJ, Musa DM, Lestico MR, et al, “Risk of Nephrotoxicity With Combination Vancomycin-Aminoglycoside Antibiotic Therapy,” <i>Pharmacotherapy</i>, 1990, 10(6):378-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2287556\">[PubMed 2287556]</a></p>\n<p>4. Rybak MJ, Frankowski JJ, Edwards DJ, et al, “Alanine Aminopeptidase and Beta2-Microglobulin Excretion in Patients Receiving Vancomycin and Gentamicin,” <i>Antimicrob Agents Chemother</i>, 1987, 31(10):1461-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2893584\">[PubMed 2893584]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2842":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Potassium-Sparing Diuretics</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Routine combined use of an angiotensin converting enzyme inhibitor, angiotensin II blocker, and aldosterone antagonist such as spironolactone is not recommended for patients with heart failure with reduced ejection fraction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> These agents are often, and appropriately so, used concomitantly in the treatment of severe CHF. It seems prudent to monitor for increased incidence of hyperkalemia if potassium-sparing diuretics and angiotensin-converting enzyme inhibitors are used concomitantly.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril*, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride*, Eplerenone, Spironolactone, Triamterene</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Life-threatening hyperkalemia has developed in at least 5 patients receiving angiotensin-converting enzyme inhibitors (ACEI) (ie, enalapril, and captopril) following the addition of amiloride/hydrochlorothiazide to their regimen.<sup>1</sup> All 5 patients had diabetes, and 4 had renal impairment. Four patients suffered cardiac arrhythmias, and 2 suffered cardiac arrest/death. Other similar cases have been reported.<sup>2</sup> A report from the RALES trial demonstrated positive clinical effects from adding spironolactone (25 mg/day) to the regimens of NYHA class III/IV heart failure patients that also contained an ACEI, a loop diuretic, and digoxin (in most cases).<sup>3</sup> One review of 523 ACEI-treated patients admitted to a hospital due to hyperkalemia discovered that treatment with a potassium-sparing diuretic in the previous week increased the odds of this event by twentyfold.<sup>4</sup>The incidence of serious hyperkalemia was minimal in both the treatment and control groups. Since hyperkalemia is associated with ACEI alone, the mechanism of an interaction resulting in hyperkalemia is possibly due to an additive effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Chiu TF, Bullard MJ, Chen JC, et al, “Rapid Life-Threatening Hyperkalemia After Addition of Amiloride HCl/Hydrochlorothiazide to Angiotensin-Converting Enzyme Inhibitor Therapy,” <i>Ann Emerg Med</i>, 1997, 30(5):612-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9360571\">[PubMed 9360571]</a></p>\n<p>2. Burnakis TG and Mioduch HJ, “Combined Therapy With Captopril and Potassium Supplementation. A Potential for Hyperkalemia,” <i>Arch Intern Med</i>, 1984, 144(12):2371-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6391404\">[PubMed 6391404]</a></p>\n<p>3. Pitt B, Zannad F, Remme WJ, et al, “The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators,” <i>N Engl J Med</i>, 1999, 341(10):709-17. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10471456\">[PubMed 10471456]</a></p>\n<p>4. Juurlink DN, Mamdani M, Kopp A, et al, “Drug-drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity,” <i>JAMA</i>, 2003, 289(13):1652-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12672733\">[PubMed 12672733]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2843":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Loop Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Loop Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for symptomatic hypotension and renal failure if an angiotensin-converting enzyme (ACE) inhibitor is initiated in patients receiving loop diuretics. Correction of volume depletion by diuretic therapy interruption or diuretic dose reduction prior to ACE inhibitor initiation/dose increases is recommended. If diuretic therapy cannot be reduced (e.g., in patients with heart failure), initiating ACE inhibitors at very low doses and increasing doses in small increments may minimize this interaction. Patients who are also using a non-steroidal antiinflammatory drug (NSAID) may be particularly at risk for acute kidney injury.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 9 patients with heart failure, the blood pressure-lowering response to captopril (20 mg intravenous) was more pronounced when given after an increase in their diuretic regimen.<sup>1</sup> In a retrospective study of 73 hypertensive patients, renal insufficiency was more common among patients who received angiotensin-converting enzyme (ACE) inhibitors (19% vs 0%), and diuretic therapy was a concomitant medication in all cases of ACE inhibitor-associated renal dysfunction.<sup>2</sup> Several case reports support these clinical findings by reporting acute kidney injury and/or hypotension when ACE inhibitors were given to patients being treated with diuretics or those with relative volume depletion.<sup>3,4,5</sup><br><br>The findings of several case-control and cohort studies suggest that the risk for acute kidney injury (AKI) may be particularly high with use of the three drug combination of an ACE inhibitor/angiotensin receptor blocker, diuretic, and non-steroid antiinflammatory drug (NSAID),<sup>6,7,8,9</sup> and higher than that observed with any single drug or two drug combination.<br><br>US and Canadian furosemide product labeling warns that the risk of severe hypotension and renal failure is increased when furosemide is combined with ACE inhibitors.<sup>10,11</sup> Additionally, prescribing information for several ACE inhibitors state that the initiation of ACE inhibitors in patients who are volume- or salt-depleted (e.g., those taking diuretics) may result in excessive blood pressure reduction.<sup>12,13,14,15,16</sup> Labeling recommends a temporary interruption in diuretic therapy or a dose reduction prior to ACE inhibitor initiation.<sup>10,11,12,13,14,15,16</sup> If diuretic therapy cannot be reduced, initiating ACE inhibitors at very low doses and increasing doses in small increments with close monitoring is recommended and supported by clinical trial evidence.<sup>17</sup><br><br>The volume-depleted state induced by diuretic therapy, combined with the peripheral vasodilation and initial decrease in renal blood flow produced by the ACE inhibitor, is the likely mechanism for the exaggerated hypotensive response and renal injury associated with this drug combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Flapan AD, Davies E, Williams BC, Shaw TR, Edwards CR. The relationship between diuretic dose, and the haemodynamic response to captopril in patients with cardiac failure. <i>Eur Heart J</i>. 1992;13(7);971-975. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1644090\">[PubMed 1644090]</a></p>\n<p>2. Toto RD, Mitchell HC, Lee HC, Milam C, PettingerWA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. <i>Ann Intern Med</i>. 1991;115(7):513-519. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1883120\">[PubMed 1883120]</a></p>\n<p>3. Atkinson AB, Brown JJ, Morton JJ, et al. Captopril in a hyponatremic hypertensive: need for caution in initiating therapy. <i>Lancet</i>. 1979;1(8115):557-558. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=85145\">[PubMed 85145]</a></p>\n<p>4. Hogg KJ, Hillis WS. Captopril/metolazone-induced renal failure. <i>Lancet</i>. 1986;1(8479):501-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2869237\">[PubMed 2869237]</a></p>\n<p>5. Funck-Brentano C, Chatellier G, Alexandre JM. Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure. <i>Br Heart J</i>. 1986;55(6):596-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3013264\">[PubMed 3013264]</a></p>\n<p>6. Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: “The Triple Whammy”. <i>Nefrologia</i>. 2015;35(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26300514\">[PubMed 26300514]</a></p>\n<p>7. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. <i>Kidney Int</i>. 2015;88(2):396-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25874600\">[PubMed 25874600]</a></p>\n<p>8. Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centres. More on the “Triple Whammy”: antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database. <i>Ren Fail</i>. 2014;36(7):1166-1168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24826803\">[PubMed 24826803]</a></p>\n<p>9. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23299844\">[PubMed 23299844]</a></p>\n<p>10. Lasix (furosemide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; August 2011.</p>\n<p>11. Lasix (furosemide) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; December 2013.</p>\n<p>12. Capoten (captopril) [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; June 2012.</p>\n<p>13. Lotensin (benazepril) [prescribing information]. Suffern, NY: Novartis Pharmaceuticals Corporation; September 2012.</p>\n<p>14. Zestril (lisinopril) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2014.</p>\n<p>15. Vasotec (enalapril) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; September 2012.</p>\n<p>16. Altace (ramipril) [prescribing information]. New York, NY: Pfizer Inc; May 2013. </p>\n<p>17. Thind GS, Mahapatra RK, Johnson A, Coleman RD. Low-dose captopril titration in patients with moderate-to-severe hypertension treated with diuretics. <i>Circulation</i>. 1983;67(6):1340-1346. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6342835\">[PubMed 6342835]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2844":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for symptomatic hypotension and renal failure if an angiotensin-converting enzyme (ACE) inhibitor is initiated in patients receiving thiazide diuretics who are volume or salt depleted. Correction of volume depletion by diuretic therapy interruption or diuretic dose reduction prior to ACE inhibitor initiation/dose increases is recommended. If diuretic therapy cannot be reduced (e.g., in patients with heart failure), initiating ACE inhibitors at very low doses and increasing doses in small increments may minimize this interaction. Patients who are also using a non-steroidal antiinflammatory drug (NSAID) may be particularly at risk for acute kidney injury.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril*, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide*, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone*, Xipamide</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 9 patients with heart failure, the blood pressure-lowering response to captopril (20 mg intravenous) was more pronounced when given after an increase in their diuretic regimen.<sup>1</sup> In a retrospective study of 73 hypertensive patients, renal insufficiency was more common among patients who received angiotensin-converting enzyme (ACE) inhibitors (19% vs 0%), and diuretic therapy was a concomitant medication in all cases of ACE inhibitor-associated renal dysfunction.<sup>2</sup> Several case reports support these clinical findings by reporting acute kidney injury and/or hypotension when ACE inhibitors were given to patients being treated with diuretics or those with relative volume depletion.<sup>3,4,5</sup><br><br>The findings of several case-control and cohort studies suggest that the risk for acute kidney injury (AKI) may be particularly high with use of the three drug combination of an ACE inhibitor/angiotensin receptor blocker, diuretic, and non-steroid antiinflammatory drug (NSAID),<sup>6,7,8,9</sup> and higher than that observed with any single drug or two drug combination.<br><br>The prescribing information for several ACE inhibitors state that the initiation of ACE inhibitors in patients who are volume- or salt-depleted (e.g., those taking diuretics) may result in excessive blood pressure reduction.<sup>10,11,12,13,14</sup> Labeling recommends a temporary interruption in diuretic therapy or a dose reduction prior to ACE inhibitor initiation.<sup>10,11,12,13,14</sup> If diuretic therapy cannot be reduced, initiating ACE inhibitors at very low doses and increasing doses in small increments with close monitoring is recommended and supported by clinical trial evidence.<sup>15</sup><br><br>The volume depleted state induced by diuretic therapy, combined with the peripheral vasodilation and initial decrease in renal blood flow produced by the ACE inhibitor, is the likely mechanism for the exaggerated hypotensive response and renal injury associated with this drug combination. Although this interaction is likely to be more clinically significant with the use of loop diuretics (due to their greater potency and ability to reduce intravascular volume), caution is still warranted when initiating ACE inhibitor therapy in a patient on a thiazide diuretic.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Flapan AD, Davies E, Williams BC, Shaw TR, Edwards CR. The relationship between diuretic dose, and the haemodynamic response to captopril in patients with cardiac failure. <i>Eur Heart J</i>. 1992;13(7);971-975. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1644090\">[PubMed 1644090]</a></p>\n<p>2. Toto RD, Mitchell HC, Lee HC, Milam C, PettingerWA. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. <i>Ann Intern Med</i>. 1991;115(7):513-519. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1883120\">[PubMed 1883120]</a></p>\n<p>3. Atkinson AB, Brown JJ, Morton JJ, et al. Captopril in a hyponatremic hypertensive: need for caution in initiating therapy. <i>Lancet</i>. 1979;1(8115):557-558. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=85145\">[PubMed 85145]</a></p>\n<p>4. Hogg KJ, Hillis WS. Captopril/metolazone-induced renal failure. <i>Lancet</i>. 1986;1(8479):501-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2869237\">[PubMed 2869237]</a></p>\n<p>5. Funck-Brentano C, Chatellier G, Alexandre JM. Reversible renal failure after combined treatment with enalapril and frusemide in a patient with congestive heart failure. <i>Br Heart J</i>. 1986;55(6):596-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3013264\">[PubMed 3013264]</a></p>\n<p>6. Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: “The Triple Whammy”. <i>Nefrologia</i>. 2015;35(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26300514\">[PubMed 26300514]</a></p>\n<p>7. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. <i>Kidney Int</i>. 2015;88(2):396-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25874600\">[PubMed 25874600]</a></p>\n<p>8. Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centres. More on the “Triple Whammy”: antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database. <i>Ren Fail</i>. 2014;36(7):1166-1168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24826803\">[PubMed 24826803]</a></p>\n<p>9. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23299844\">[PubMed 23299844]</a></p>\n<p>10. Capoten (captopril) [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; June 2012.</p>\n<p>11. Lotensin (benazepril) [prescribing information]. Suffern, NY: Novartis Pharmaceuticals Corporation; September 2012.</p>\n<p>12. Zestril (lisinopril) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2014.</p>\n<p>13. Vasotec (enalapril) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; September 2012.</p>\n<p>14. Altace (ramipril) [prescribing information]. New York, NY: Pfizer Inc; May 2013. </p>\n<p>15. Thind GS, Mahapatra RK, Johnson A, Coleman RD. Low-dose captopril titration in patients with moderate-to-severe hypertension treated with diuretics. <i>Circulation</i>. 1983;67(6):1340-1346. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6342835\">[PubMed 6342835]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2845":"<p><b>Title</b> Cardiac Glycosides / Potassium-Sparing Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of cardiac glycosides if a potassium-sparing diuretic is initiated/dose increased, or increased effects if a potassium-sparing diuretic is discontinued/dose decreased. The interaction between cardiac glycosides and the potassium-sparing diuretic spironolactone, which is also an aldosterone antagonist, may be unique in that increased digoxin concentrations have been reported.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride*, Eplerenone, Spironolactone, Triamterene</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A small study in subjects taking amiloride (10 mg/day for 8 days), and subsequently administered a single intravenous dose of digoxin (15 mcg/kg), showed a reduction in the inotropic effects of the digoxin. The clinical importance was unclear. No changes in digoxin serum concentrations occurred, although changes in clearance did occur (renal clearance increased; nonrenal clearance decreased).<sup>1</sup> The mechanism for the pharmacodynamic effect is unknown.<br><br>Several small clinical studies have documented decreased digoxin clearance and increased digoxin concentrations associated with concurrent use of spironolactone.<sup>2,3,4</sup> The mechanism for this apparent pharmacokinetic interaction are uncertain, and it is not clear if this is unique to spironolactone (vs. other potassium-sparing diuretics). An important complicating factor in the discussion of this possible interaction is that spironolactone and/or its metabolites may interfere with many of the different assays used to determine digoxin concentrations.<sup>5,6,7,8,9,10,11</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Waldorff S, Hansen PB, Kjaergard H, et al, “Amiloride-Induced Changes in Digoxin Dynamics and Kinetics: Abolition of Digoxin-Induced Inotropism With Amiloride,” <i>Clin Pharmacol Ther</i>, 1981, 30(2):172-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7249501\">[PubMed 7249501]</a></p>\n<p>2. Waldorff S, Andersen JD, Heeboll-Nielsen N, et al, “Spironolactone-Induced Changes in Digoxin Kinetics,” <i>Clin Pharmacol Ther</i>, 1978, 24:162-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=679595\">[PubMed 679595]</a></p>\n<p>3. Krusteva E, “Changes in the Plasma Levels and Basic Pharmacokinetic Parameters of Digoxin Used in Combination with Gentamicin, Amiodarone and Spironolactone,” <i>Folia Med (Plovdiv)</i>, 1992, 34:24-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1339769\">[PubMed 1339769]</a></p>\n<p>4. Hedman A, Angelin B, Arvidsson A, et al, “Digoxin-Interactions in Man: Spironolactone Reduces Renal but Not Biliary Digoxin Clearance,” <i>Eur J Clin Pharmacol</i>, 1992, 42:481-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1606994\">[PubMed 1606994]</a></p>\n<p>5. Dasgupta A, Saffer H, Wells A, et al, “Bidirectional (Positive/Negative) Interference of Spironolactone, Canrenone, and Potassium Canrenoate on Serum Digoxin Measurement: Elimination of Interference by Measuring Free Digoxin or Using a Chemiluminescent Assay for Digoxin,” <i>J Clin Lab Anal</i>, 2002, 16:172-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12112389\">[PubMed 12112389]</a></p>\n<p>6. Dasgupta A, Tso G, Wells A, “Effect of Spironolactone, Potassium Canrenoate and Their Common Metabolite Canrenone on Serum Digoxin Measurement by Digoxin III, a New Digoxin Immunoassay,” <i>Ther Drug Monit</i>, 2008, 30:744-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18824952\">[PubMed 18824952]</a></p>\n<p>7. Morris RG, Frewin DB, Taylor WB, et al, “The Effect of Renal and Hepatic Impairment and of Spironolactone on Digoxin Immunoassays,” <i>Eur J Clin Pharmacol</i>, 1988, 34:233-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3396618\">[PubMed 3396618]</a></p>\n<p>8. Morris RG, Lagnado PY, Lehmann DR, et al, “Spironolactone as a Source of Interference in Commercial Digoxin Immunoassays,” <i>Ther Drug Monit</i>, 1987, 9:208-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3617160\">[PubMed 3617160]</a></p>\n<p>9. Pleasants RA, Williams DM, Porter RS, et al, “Reassessment of Cross-Reactivity of Spironolactone Metabolites with Four Digoxin Immunoassays,” <i>Ther Drug Monit</i>, 1989, 11:200-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2655203\">[PubMed 2655203]</a></p>\n<p>10. Silber B, Sheiner LB, Powers JL, et al, “Spironolactone-Associated Digoxin Radioimmunoassay Interference,” <i>Clin Chem</i>, 1979, 25:48-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=761378\">[PubMed 761378]</a></p>\n<p>11. Steimer W, Muller C, Eber B, “Digoxin Assays: Frequent, Substantial, and Potentially Dangerous Interference by Spironolactone, Canrenone, and Other Steroids,” <i>Clin Chem</i>, 2002, 48:507-16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11861441\">[PubMed 11861441]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2846":"<p><b>Title</b> QuiNIDine / Potassium-Sparing Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of quinidine if a potassium-sparing diuretic is initiated/dose increased, or increased effects if a potassium-sparing diuretic is discontinued/dose decreased.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride*, Eplerenone, Spironolactone, Triamterene</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A single dose study in 10 patients with inducible ventricular tachycardia receiving quinidine showed reduced therapeutic effects of the quinidine, and increased incidence of ventricular arrhythmias, following 3 days of amiloride administration.<sup>1</sup> Electrophysiologic studies revealed prolonged ventricular conduction. The mechanism for this interaction may be related to a combined effect of the agents on myocardial sodium channels.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wang L, Sheldon RS, Mitchell LB, et al, “Amiloride-Quinidine Interaction: Adverse Outcomes,” <i>Clin Pharmacol Ther</i>, 1994, 56(6 Pt 1):659-67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7995008\">[PubMed 7995008]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2847":"<p><b>Title</b> Potassium-Sparing Diuretics / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Salicylates do not appear to alter the pharmacodynamic effect(s) of Potassium-Sparing Diuretics. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone*, Triamterene</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A study in 5 hypertensive patients controlled by spironolactone showed no change in control when administered aspirin (2.4-4.8 g/day) for 6 weeks.<sup>1</sup> Serum electrolytes, patient weight, and BUN remained unchanged.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hollifield JW, “Failure of Aspirin to Antagonize the Antihypertensive Effect of Spironolactone in Low-Resin Hypertension,” <i>South Med J</i>, 1976, 69(8):1034-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=785608\">[PubMed 785608]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2848":"<p><b>Title</b> Vitamin K Antagonists / Potassium-Sparing Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Potassium-Sparing Diuretics may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone, Triamterene</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> Nine normal subjects received spironolactone 200 mg/day for 7 days, then a single dose of warfarin.<sup>1</sup> The prothrombin time was measured to be approximately 25% lower than when measured outside the influence of the diuretic. The mechanism for this interaction is suggested to be related to an increase in the serum concentration of clotting factors resulting from the diuresis of plasma water.<sup>1,2</sup> The clinical significance of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. O’Reilly RA, “Spironolactone and Warfarin Interaction,” <i>Clin Pharmacol Ther</i>, 1980, 27(2):198-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7353340\">[PubMed 7353340]</a></p>\n<p>2. Laizure SC, Madlock L, Cyr M, et al, “Decreased Hypoprothrombinemic Effect of Warfarin Associated With Furosemide,” <i>Ther Drug Monit</i>, 1997, 19(3):361-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9200780\">[PubMed 9200780]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2849":"<p><b>Title</b> Nitroglycerin / Acetylcysteine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Acetylcysteine may enhance the vasodilatory effect of Nitroglycerin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Several, though not all, reports describe the ability of acetylcysteine to enhance the vasodilatory effects of nitroglycerin, even in light of existing nitrate tolerance.<sup>1,2,3,4</sup> The mechanism of these interactions is likely related to the ability of acetylcysteine to donate sulfhydryl groups which are subsequently used by the nitrate to increase cyclic guanylic acid. The cyclic guanylic acid causes relaxation of vascular smooth muscle.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Horowitz JD, Antman EM, Lorell BH, et al, “Potentiation of the Cardiovascular Effect of Nitroglycerin by N-Acetylcysteine,” <i>Circulation</i>, 1983, 68(6):1247-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6139183\">[PubMed 6139183]</a></p>\n<p>2. Winniford MD, Kennedy PL, Wells PJ, et al, “Potentiation of Nitroglycerin-Induced Coronary Dilatation by N-Acetylcysteine,” <i>Circulation</i>, 1986, 73(1):138-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3079676\">[PubMed 3079676]</a></p>\n<p>3. Torresi J, Horowitz JD, and Dusting GJ, “Prevention and Reversal of Tolerance to Nitroglycerin With N-Acetylcysteine,” <i>J Cardiovasc Pharmacol</i>, 1985, 7(4):777-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2410721\">[PubMed 2410721]</a></p>\n<p>4. Packer M, Lee WH, Kessler PD, et al, “Prevention and Reversal of Nitrate Tolerance in Patients With Congestive Heart Failure,” <i>N Engl J Med</i>, 1987, 317(13):799-804. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3114637\">[PubMed 3114637]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2856":"<p><b>Title</b> Vitamin K Antagonists / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Isoniazid may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A single case report describes an increased hypoprothrombinemic response to warfarin after the addition of para-aminosalicylate sodium (PAS) and isoniazid.<sup>1</sup> An additional report describes a similar response when a patient increased his dose of isoniazid (the patient was not taking PAS).<sup>2</sup> The mechanism of these reported interactions is unknown, but is more likely related to isoniazid than PAS. It is possible that isoniazid inhibits the hepatic metabolism of warfarin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Self TH, “Interaction of Warfarin and Aminosalicylic Acid,” <i>JAMA</i>, 1973, 223(11):1285. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4739335\">[PubMed 4739335]</a></p>\n<p>2. Rosenthal AR, Self TH, Baker ED, et al, “Interaction of Isoniazid and Warfarin,” <i>JAMA</i>, 1977, 238(20):2177. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=578833\">[PubMed 578833]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2857":"<p><b>Title</b> Amiodarone / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternative antilipemic agent. The risk of subtherapeutic amiodarone serum concentrations when such is being used for the treatment of malignant arrhythmias can be very large. The effect (ie, reduced risk) of separating doses of these agents is unknown. Amiodarone should be administered at least 1 hour before or 4 hours after colesevelam.<sup>1</sup> Similar dosing with other agents seems warranted.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin*, Colesevelam, Colestipol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The bioavailability of a single dose of amiodarone was reduced by approximately 50% in 11 patients who received 4 doses of cholestyramine resin (4 g/dose) administered every 90 minutes following the dose of amiodarone. The half-life of amiodarone was reduced to a similar degree.<sup>2</sup> The mechanism of this interaction is unknown, but may be related to the binding of amiodarone to cholestyramine in the GI tract, thereby inhibiting its absorption. A similar effect may occur when amiodarone is administered with other bile acid sequestrants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Welchol [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc, 2006.</p>\n<p>2. Nitsch J and Luderitz B, “Acceleration of Amiodarone Elimination by Cholestyramine,” <i>Dtsch Med Wochenschr</i>, 1986, 111(33):1241-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3743429\">[PubMed 3743429]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2858":"<p><b>Title</b> Amiodarone / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Amiodarone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to cimetidine in patients receiving amiodarone. If this combination cannot be avoided, monitor for increased amiodarone concentrations/effects with cimetidine initiation/dose increase or decreased concentrations/effects with cimetidine discontinuation/dose decrease.</p> \n<p><b>Discussion</b> The serum concentrations of amiodarone increased by approximately 38% on average in 12 patients within a week after the initiation of cimetidine (1200 mg/day).<sup>1</sup> Only 8 of the 12 patients experienced an increase in amiodarone concentrations. <br><br>This interaction is likely the result of cimetidine inhibition of enzymes mediating amiodarone metabolism, including CYP3A4. Given the long half-life of amiodarone it is probable that amiodarone concentrations would continue to rise with continued cimetidine dosing. In addition, the decrease in amiodarone concentrations following the discontinuation of cimetidine would likely take several weeks.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hogan C, Landau S, Tepper D, et al, “Cimetidine-Amiodarone Interaction,” <i>J Clin Pharmacol</i>, 1988, 28:909.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2860":"<p><b>Title</b> Cardiac Glycosides / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of Cardiac Glycosides. <b>Severity</b> Major <b>Onset</b> Delayed (Sequence Important) <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Reduce the dose of cardiac glycosides by 30% to 50% or reduce the frequency of administration when initiating concomitant amiodarone therapy. Monitor for increased serum concentrations and toxic effects (eg, gastrointestinal symptoms, visual disturbances, cardiac arrhythmias) of cardiac glycosides.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin*, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Numerous studies have shown that the addition of amiodarone to oral digoxin therapy increases serum digoxin levels by 69% to 104%,<sup>1,2,3,4,5</sup> increases digoxin AUC 32% to 68%,<sup>5,6,7</sup> and increases digoxin maximum serum concentration (Cmax) by more than 100%.<sup>6,7</sup> Even greater changes, with increases of 147% to 235% in serum digoxin concentrations, have been reported in 9 pediatric patients after the addition of amiodarone to stable digoxin therapy.<sup>8</sup> In support of these studies, several case reports describe elevations in digoxin concentrations<sup>9,10,11,12</sup> and development of digoxin toxicity<sup>10,11</sup> when amiodarone was initiated in digoxin treated patients. Cases of amiodarone initiation leading to digitoxin toxicity and elevated serum concentrations have also been reported.<sup>13</sup><br><br>The prescribing information for both digoxin and amiodarone warns of this interaction and recommends a 30% to 50% dose reduction in digoxin dose upon initiation of amiodarone therapy. Additional monitoring of serum digoxin levels as well as monitoring for signs and symptoms of digoxin toxicity is recommended if these agents are combined.<sup>14,15</sup> Amiodarone prescribing information states that these warnings likely apply to digitoxin therapy as well.<sup>15</sup><br><br>The mechanism of this interaction is likely due to amiodarone inhibition of P-glycoprotein (P-gp), a transporter responsible for digoxin and digitoxin efflux.<sup>14,15,16</sup> P-gp inhibition in the gastrointestinal tract, and the resulting increase in bioavailability, is likely responsible for the majority of this interaction. In support of this mechanism, changes in digoxin pharmacokinetics associated with amiodarone therapy are greater when digoxin is given orally compared to intravenously,<sup>3,6,17</sup> and this interaction has been reported in a patient on chronic hemodialysis where renal clearance was not a factor.<sup>9</sup> Amiodarone inhibition of CYP3A4 may also play a role in cases of digitoxin toxicity,<sup>13,15</sup> and amiodarone-induced hypothyroidism has also been implicated in a case of digoxin toxicity.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Moysey JO, Jaggarao NS, Grundy EN, Chamberlain DA. Amiodarone increases plasma digoxin concentrations. <i>Br Med J (Clin Res Ed)</i>. 1981;282(6260):272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6779981\">[PubMed 6779981]</a></p>\n<p>2. Oetgen WJ, Sobol SM, Tri TB, Heydorn WH, Rakita L. Amiodarone-digoxin interaction. Clinical and experimental observations. <i>Chest</i>. 1984;86(1):75-79. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6734297\">[PubMed 6734297]</a></p>\n<p>3. Nademanee K, Kannan R, Hendrickson J, Ookhtens M, Kay I, Singh BN. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms, and therapeutic implications. <i>J Am Coll Cardiol</i>. 1984;4(1):111-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6736437\">[PubMed 6736437]</a></p>\n<p>4. Douste-Blazy P, Montastruc JL, Bonnet B, Auriol P, Conte D, Bernadet P. Influence of amiodarone on plasma and urine digoxin concentrations. <i>Lancet</i>. 1984;1(8382):905. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6143206\">[PubMed 6143206]</a></p>\n<p>5. Robinson K, Johnston A, Walker S, Mulrow JP, McKenna WJ, Holt DW. The digoxin-amiodarone interaction. <i>Cardiovasc Drugs Ther</i>. 1989;3(1):25-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2487521\">[PubMed 2487521]</a></p>\n<p>6. Santostasi G, Fantin M, Maragno I, Gaion RM, Basadonna O, Dalla-Volta S. Effects of amiodarone on oral and intravenous digoxin kinetics in healthy subjects. <i>J Cardiovasc Pharmacol</i>. 1987;9(4):385-390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2438499\">[PubMed 2438499]</a></p>\n<p>7. Maragno I, Santostasi G, Gaion RM, Paleari C. Influence of amiodarone on oral digoxin bioavailability in healthy volunteers. <i>Int J Clin Pharmacol Res</i>. 1984;4(2):149-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6469441\">[PubMed 6469441]</a></p>\n<p>8. Koren G, Hesslein PS, MacLeod SM. Digoxin toxicity associated with amiodarone therapy in children. <i>J Pediatr</i>. 1984;104(3):467-470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6707801\">[PubMed 6707801]</a></p>\n<p>9. Mingardi G. Amiodarone and plasma digoxin levels. <i>Lancet</i>. 1984;1(8388):1238. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6144946\">[PubMed 6144946]</a></p>\n<p>10. Ben-Chetrit E, Ackerman Z, and Eliakim M. Amiodarone-associated hypothyroidism - a possible cause of digoxin intoxication. <i>Am J Med Sci</i>. 1985;289(3):114-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3976714\">[PubMed 3976714]</a></p>\n<p>11. Klein HO, Beker B, DiSegni E, Kaplinksy E. Asystole produced by the combination of amiodarone and digoxin. <i>Am Heart J</i>. 1987;113(2, pt 1):399-400. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3544756\">[PubMed 3544756]</a></p>\n<p>12. DeVore KJ, Hobbs RA. Plasma digoxin concentration fluctuations associated with timing of plasma sampling and amiodarone administration. <i>Pharmacotherapy</i>. 2007;27(3):472-475. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17316159\">[PubMed 17316159]</a></p>\n<p>13. Laer S, Scholz H, Buschmann I, Thoenes M, Meinertz T. Digitoxin intoxication during concomitant use of amiodarone. <i>Eur J Clin Pharmacol</i>. 1998;54(1):95-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9591938\">[PubMed 9591938]</a></p>\n<p>14. Digoxin [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2012. </p>\n<p>15. <i>Cordarone</i> (amiodarone) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; October 2011.</p>\n<p>16. Pauli-Magnus C, Murdter T, Godel A, et al. P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin, and beta-acetyldigoxin. <i>Naunyn Schmiedebergs Arch Pharmacol</i>. 2001;363(3):337-343. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11284449\">[PubMed 11284449]</a></p>\n<p>17. Fenster PE, White NW Jr, Hanson CD. Pharmacokinetic evaluation of the digoxin-amiodarone interaction. <i>J Am Coll Cardiol</i>. 1985;5(1):108-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3964797\">[PubMed 3964797]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2861":"<p><b>Title</b> Beta-Blockers / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amiodarone may enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased signs and symptoms of bradycardia with beta-blockers (possibly to the point of cardiac arrest) if amiodarone is initiated/dose increased, or decreased effects if amiodarone is discontinued/dose decreased. Ophthalmic beta-blockers are likely of little concern.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol*, Nadolol, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol*, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Considering that both amiodarone and beta-blockers are capable of beta-adrenergic antagonism, their combined use has the potential to result in adverse effects associated with excessive beta-receptor antagonism such as bradycardia, sinus arrest, and AV block.<sup>1</sup> One randomized controlled trial of 412 patients with implantable cardioverter defibrillators reported a significantly greater rate of bradycardia with amiodarone plus a beta-blocker (metoprolol, carvedilol, or bisoprolol) (6.4%) vs. either a beta-blocker alone (0.7%) or sotalol alone (1.5%) (p=0.009).<sup>2</sup> This interaction has also been discussed in a number of case reports.<sup>3,4,5</sup> <br><br>The primary mechanism of this interaction is likely additive beta-blockade given the known pharmacological effects of these drugs. However, amiodarone (a known inhibitor of several enzymes and transporters involved in drug disposition<sup>1</sup>) may also increase the concentration of certain beta-blockers, further enhancing the likelihood of a significant interaction (e.g., increased metoprolol concentrations (and beta-blockade) via CYP2D6 inhibition). Such additional effects may explain observed differences among the beta-blockers in the degree to which they interact with amiodarone (e.g., less with atenolol vs. metoprolol<sup>3</sup>).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Cordarone (amiodarone). Philadelphia, PA: Wyeth Pharmaceuticals Inc., 04/08.</p>\n<p>2. Connolly SJ, Dorian P, Roberts RS, et al, “Comparison of Beta-Blockers, Amiodarone Plus Beta-Blockers, or Sotalol for Prevention of Shocks from Implantable Cardioverter Defibrillators: the OPTIC Study: a Randomized Trial,” <i>JAMA</i>, 2006, 295(2):165-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16403928\">[PubMed 16403928]</a></p>\n<p>3. Leor J, Levartowsky D, Sharon C, et al, “Amiodarone and Beta-Adrenergic Blockers: An Interaction With Metoprolol But Not With Atenolol,” <i>Am Heart J</i>, 1988, 116(1 Pt 1):206-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3394625\">[PubMed 3394625]</a></p>\n<p>4. Warren R, Vohra J, Hunt D, et al, “Serious Interactions of Sotalol With Amiodarone and Flecainide,” <i>Med J Aust</i>, 1990, 152(5):277. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2123962\">[PubMed 2123962]</a></p>\n<p>5. Derrida JP, Ollagnier J, Benaim R, et al, “Amiodarone and Propranolol; A Dangerous Combination?” <i>Nouv Presse Med</i>, 1979, 8(17):1429. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=482119\">[PubMed 482119]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2862":"<p><b>Title</b> Theophylline Derivatives / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amiodarone may decrease the metabolism of Theophylline Derivatives. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for toxic effects of theophylline derivatives if amiodarone is initiated or the dose is increased. The effects may take several days to weeks to occur or resolve.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. Serum theophylline concentrations more than doubled in an 86-year-old man within 9 days of initiating amiodarone therapy.<sup>1</sup> Symptoms of theophylline toxicity accompanied the increased serum concentrations. Symptoms resolved within 2 days of discontinuing the theophylline. The mechanism of this interaction is likely related to the ability of amiodarone to inhibit the hepatic enzymes responsible for theophylline metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Soto J, Sacristan JA, Arellano F, et al, “Possible Theophylline-Amiodarone Interaction,” <i>DICP</i>, 1990, 24(11):1115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2275239\">[PubMed 2275239]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2863":"<p><b>Title</b> Vitamin K Antagonists / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Amiodarone may enhance the anticoagulant effect of Vitamin K Antagonists. Amiodarone may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Major <b>Onset</b> Delayed <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients extra closely for evidence of increased anticoagulant effects if amiodarone is initiated/dose increased, or decreased effects if amiodarone is discontinued/dose decreased, though due to the long half-life of amiodarone, any interaction may persist for several days/weeks following any dose decrease or discontinuation. An empiric warfarin dosage reduction of 30% to 50% at the initiation of amiodarone might be considered, with close monitoring of anticoagulant effect to further refine optimal dosing.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Elderly patients (average age = 76 years) stable on warfarin therapy had more than twice the risk of requiring hospitalization due to a hemorrhage within 30 days of starting amiodarone as compared to similar patients who did not receive amiodarone (0.8% vs. 0.3%; HR=2.45) in an observational study of 7,124 warfarin-treated patients being started on amiodarone and 7,124 matched controls.<sup>1</sup> The data used in this study did not include actual INR values, so degree of INR control at the time of comparison cannot be assessed. These findings are in contrast with those of a cohort study that found no difference in major hemorrhagic events between warfarin users receiving concurrent amiodarone and those not receiving amiodarone (14.8% vs. 14.2%).<sup>2</sup> This cohort consisted of a smaller number of at-risk patients (n=1,260 receiving amiodarone and warfarin vs. 9,147 in the warfarin-only group), patients who were slightly younger (average of approximately 64 years of age), and patients who were followed for a shorter duration (7-day follow-up vs. a 30-day follow-up); though it is not clear the extent to which these or other design/demographic factors contributed to the different conclusions between these two observational studies.<br><br>Several published case reports or case series describe an increase in the hypoprothrombinemic effects of warfarin (and other coumarin derivatives, including acenocoumarol) following the addition of amiodarone.<sup>3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19</sup> A doubling of the prothrombin time has been reported in some cases. The effects typically take at least one week to become apparent, and may increase over the course of the next several weeks. Likewise, the reversal of the effects following discontinuation of the amiodarone may take several weeks. The primary mechanism of these interactions is likely related to the ability of amiodarone to inhibit one or more of the enzymes responsible for warfarin and acenocoumarol metabolism.<sup>20</sup> The iodine content of amiodarone may, following chronic dosing, cause hyperthyroidism which may in turn alter the body's sensitivity to warfarin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lam J, Gomes T, Juurlink DN, Mamdani MM, Pullenayegum EM, Kearon C, et al. Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone. <i>Am J Cardiol</i>. 2013;112(3):420-423. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23664078\">[PubMed 23664078]</a></p>\n<p>2. Zhang K, Young C, Berger J. Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. <i>J Manag Care Pharm</i>. 2006;12(8):640-648. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17269842\">[PubMed 17269842]</a></p>\n<p>3. Martinowitz U, Rabinovich J, Goldfarb D, et al. Interaction between warfarin sodium and amiodarone. <i>N Engl J Med</i>. 1981;304(11):671-672. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7453749\">[PubMed 7453749]</a></p>\n<p>4. Rees A, Dalal JJ, Reid PG, et al. Dangers of amiodarone and anticoagulant treatment. <i>Br Med J</i>. 1981;282(6278):1756-1757. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6786610\">[PubMed 6786610]</a></p>\n<p>5. Serlin MJ, Sibeon RG, Green GJ. Dangers of amiodarone and anticoagulant treatment. <i>Br Med J</i>. 1981;283(6283):58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6788267\">[PubMed 6788267]</a></p>\n<p>6. Hamer A, Peter T, Mandel WJ, et al. The potentiation of warfarin anticoagulation by amiodarone. <i>Circulation</i>. 1982;65(5):1025-1029. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7074739\">[PubMed 7074739]</a></p>\n<p>7. McGovern B, Garan H, Kelly E, et al. Adverse reactions during treatment with amiodarone. <i>Br Med J</i>. 1983;287(6386):175-180. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6409240\">[PubMed 6409240]</a></p>\n<p>8. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. <i>Am Heart J</i>. 1985;109(5 Pt 1):975-983. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3158188\">[PubMed 3158188]</a></p>\n<p>9. Cheung B, Lam FM, Kumana CR. Insidiously evolving, occult drug interaction involving warfarin and amiodarone. <i>Br Med J</i>. 1996;312(7023):107-108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8555895\">[PubMed 8555895]</a></p>\n<p>10. Arboix M, Frati ME, Laporte JR. The potentiation of acenocoumarol anticoagulant effects by amiodarone. <i>Br J Clin Pharmacol</i>. 1984;18(3):355-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487475\">[PubMed 6487475]</a></p>\n<p>11. El Allaf D, Sprynger M, Carlier J. Potentiation of the action of oral anticoagulants by amiodarone. <i>Acta Clin Belg</i>. 1984;39(5):306-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6524252\">[PubMed 6524252]</a></p>\n<p>12. Arboix M, Frati ME, Laporte JR. The potentiation of acenocoumarol anticoagulant effect by amiodarone. <i>Br J Clin Pharmacol</i>. 1984;18(3):355-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6487475\">[PubMed 6487475]</a></p>\n<p>13. Richard C, Riou B, Berdeaux A, et al. Prospective study of the potentiation of acenocoumarol by amiodarone. <i>Eur J Clin Pharmacol</i>. 1985;28(6):625-629. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4065185\">[PubMed 4065185]</a></p>\n<p>14. Pini M, Manotti C, Quintavalla R. Interaction between amiodarone and acenocoumarin. <i>Thromb Haemost</i>. 1985;30;54(2):549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4082092\">[PubMed 4082092]</a></p>\n<p>15. Caraco Y, Raveh D, Flugelman M, et al. Enhanced anticoagulant effect of acenocoumarol induced by amiodarone coadministration. <i>Isr J Med Sci</i>. 1988;24(11):688-689. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3215763\">[PubMed 3215763]</a></p>\n<p>16. Fondevila C, Meschengieser S, Lazzari MA. Amiodarone potentiates acenocoumarin. <i>Thromb Res</i>. 1989;53(2):203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2922709\">[PubMed 2922709]</a></p>\n<p>17. Fondevila C, Meschengieser S, Lazzari M. Amiodarone-acenocoumarin interaction. <i>Thromb Haemost</i>. 1991;65(3):328. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1878066\">[PubMed 1878066]</a></p>\n<p>18. Caraco Y, Chajek-Shaul T. The incidence and clinical significance of amiodarone and acenocoumarol interaction. <i>Thromb Haemost</i>. 1989;62(3):906-908. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2595664\">[PubMed 2595664]</a></p>\n<p>19. Baettig D, Tillement JP, Baumann P. Interaction between mianserin and acenocoumarin: a single case study. <i>Int J Clin Pharmacol Ther</i>. 1994;32(4):165-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8032574\">[PubMed 8032574]</a></p>\n<p>20. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. <i>Clin Pharmacol Ther</i>. 1992;51(4):398-407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1563209\">[PubMed 1563209]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2864":"<p><b>Title</b> Tricyclic Antidepressants / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Disulfiram may enhance the adverse/toxic effect of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A single report describes 2 disulfiram-stable patients who developed dizziness, disorientation, and hallucinations following the addition of amitriptyline.<sup>1</sup> The mechanism of this presumed interaction is unknown, however, it may be related to the ability of disulfiram to inhibit the hepatic enzymes responsible for amitriptyline metabolism. The effect on other tricyclic antidepressants is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Maany I, Hayashida M, Pfeffer SL, et al, “Possible Toxic Interaction Between Disulfiram and Amitriptyline,” <i>Arch Gen Psychiatry</i>, 1982, 39(6):743-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7092508\">[PubMed 7092508]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2866":"<p><b>Title</b> Alpha2-Agonists / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists. <b>Severity</b> Moderate <b>Onset</b> Delayed <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Due to the risk of this interaction, consider avoiding these combinations of agents. If combination used, monitor for decreased therapeutic effects of alpha<sub>2</sub>-agonists if a tricyclic antidepressant is initiated/dose increased, or increased effects if a tricyclic antidepressant is discontinued/dose decreased. Further, exercise great caution if discontinuing an alpha<sub></sub>-agonist in a patient receiving a tricyclic antidepressant. Ensure a very gradual withdrawal, and monitor for signs and symptoms of hypertensive crises.</p>\n<div>\n <p><b>Alpha2-Agonists Interacting Members</b> CloNIDine*, Dexmedetomidine, GuanFACINE*, Lofexidine, Methyldopa, Moxonidine, Rilmenidine, TiZANidine<br><b>Exceptions</b> Apraclonidine, Brimonidine (Ophthalmic)</p>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine*, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine*, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The addition of a tricyclic antidepressant to a clonidine-stable patient has resulted in an increase in blood pressure in a number of reports.<sup>1,2,3,4</sup> The blood pressure change usually took a few days to develop (although a report describes such occurring within 24 hours<sup>3</sup>), and has resulted in hypertensive crisis in some cases. Similarly, a report of a guanfacine-stable patient showed increases in blood pressure following a few days of therapy with amitriptyline and later imipramine.<sup>5</sup> The patient's blood pressure returned to pretricyclic values following discontinuation of the agent. In another case, a patient experiencing minimal opioid withdrawal symptoms with lofexidine saw a marked increase in symptoms after being given desipramine.<sup>6</sup> Symptoms ameliorated over 24 hrs after discontinuing desipramine.<sup>6</sup> In addition, the rebound hypertension that might occur following abrupt discontinuation of clonidine may be exacerbated in the presence of tricyclic antidepressants.<sup>7</sup> <br><br>The mechanism for these interactions is not established. The ability of tricyclic antidepressants to enhance the pressor response to catecholamines might partially explain this latter exaggeration of response to clonidine withdrawal.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Briant RH, Reid JL, and Dollery CT, “Interaction Between Clonidine and Desipramine in Man,” <i>Br Med J</i>, 1973, 1(5852):522-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4571186\">[PubMed 4571186]</a></p>\n<p>2. Coffler DE, “Antipsychotic Drug Interaction,” <i>Drug Intell Clin Pharm</i>, 1976, 10:114.</p>\n<p>3. Hui KK, “Hypertensive Crisis Induced by Interaction of Clonidine With Imipramine,” <i>J Am Ger Soc</i>, 1983, 31(3):164-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6827017\">[PubMed 6827017]</a></p>\n<p>4. Cubeddu LX, Cloutier G, Gross K, et al, “Bupropion Does Not Antagonize Cardiovascular Actions of Clonidine in Normal Subjects and Spontaneously Hypertensive Rats,” <i>Clin Pharmacol Ther</i>, 1984, 35(5):576-84. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6424997\">[PubMed 6424997]</a></p>\n<p>5. Buckley M and Feely J, “Antagonism of Antihypertensive Effect of Guanfacine by Tricyclic Antidepressants,” <i>Lancet</i>, 1991, 337(8750):1173-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1674059\">[PubMed 1674059]</a></p>\n<p>6. Keaney F, Crimlisk H, Bean J. Lofexidine and desipramine: interaction results in breakthrough opioid withdrawal symptoms. <i>Int J Psychiatry Clin Pract</i>. 2002;6(3):179-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24945207\">[PubMed 24945207]</a></p>\n<p>7. Stiff JL and Harris DB, “Clonidine Withdrawal Complicated by Amitriptyline Therapy,” <i>Anesthesiology</i>, 1983, 59(1):73-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6859615\">[PubMed 6859615]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2868":"<p><b>Title</b> Tricyclic Antidepressants / Lithium</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lithium may enhance the neurotoxic effect of Tricyclic Antidepressants. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The combination of a tricyclic antidepressant and lithium should be undertaken with great caution. When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome (e.g., confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia).</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Reports of significant neurotoxicity (tremor, changes in cognition, ataxia, seizures) and serotonin syndrome accompany concomitant use of lithium and tricyclic antidepressants.<sup>1,2,3</sup> The negative effects appear to be more likely to occur in the elderly. The mechanism of this interaction is unknown. Both agents possess the ability to lower seizure threshold. Further, both agents affect central neurotransmitters. Conversely, lithium is commonly used to augment the antidepressant effects of tricyclics.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Austin LS, Arana GW, and Melvin JA, “Toxicity Resulting From Lithium Augmentation of Antidepressant Treatment in Elderly Patients,” <i>J Clin Psychiatry</i>, 1990, 51(8):344-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2380160\">[PubMed 2380160]</a></p>\n<p>2. Lafferman J, Solomon K, and Ruskin P, “Lithium Augmentation for Treatment-Resistant Depression in the Elderly,” <i>J Geriat Psychiatry Neurol</i>, 1988, 1(1):49-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3150926\">[PubMed 3150926]</a></p>\n<p>3. Solomon JG, “Seizures During Lithium-Amitriptyline Therapy,” <i>Postgrad Med</i>, 1979, 66(3):145-6, 148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=112590\">[PubMed 112590]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2869":"<p><b>Title</b> Tricyclic Antidepressants / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> It is generally recommended that patients receiving serotonergic antidepressants (eg, tricyclics, SSRI, MAOI) should not add St Johns Wort to their medication regimen due to the theoretical potential of serotonin syndrome. Monitor for decreased effects of tricyclic antidepressants during coadministration of St Johns Wort.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The AUC for amitriptyline was reduced by an average of 22% in 12 patients when coadministered with St Johns Wort for 14 days.<sup>1</sup> The AUC of nortriptyline, the active metabolite of amitriptyline, was reduced by 41%. The mechanism of this interaction may be related to the ability of St Johns Wort to induce metabolic enzymes. The clinical significance of this interaction is unknown. The combination of St Johns Wort and a tricyclic antidepressant also increases the risk of serotonin syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Johne A, Schmider J, Brockmoller J, et al, “Decreased Plasma Levels of Amitriptyline and Its Metabolites on Comedication with an Extract from St. John's Wort (Hypericum perforatum),” <i>J Clin Psychopharmacol</i>, 2002, 22(1):46-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11799342\">[PubMed 11799342]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2870":"<p><b>Title</b> Vitamin K Antagonists / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased prothrombin times (PT)/toxic effects of coumarin derivatives if a tricyclic antidepressant is initiated/dose increased, or decreased effects if a tricyclic is discontinued/dose decreased.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline*, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline*, Protriptyline, Trimipramine</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The effects of tricyclic antidepressants on oral anticoagulant therapy appear unpredictable and of only minor importance. An 8-day study in 6 normal subjects showed a threefold increase in dicumarol half-life when coadministered with nortriptyline.<sup>1,2</sup> A 9-day study in 12 normal subjects using nortriptyline or amitriptyline and dicumarol or warfarin failed to show a consistent effect.<sup>3</sup> Other reports are likewise inconsistent in their findings.<sup>4</sup> The mechanism of such interactions, though not established, might be related to tricyclic-induced decreases in anticoagulant metabolism, or changes in GI motility which might result in increased anticoagulant absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vesell ES, Passananti GT, and Greene FE, “Impairment of Drug Metabolism in Man by Allopurinol and Nortriptyline,” <i>N Engl J Med</i>, 1970, 283(27):1484-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4098480\">[PubMed 4098480]</a></p>\n<p>2. Vesell ES, Passananti GT, and Aurori KC, “Anomalous Results of Studies on Drug Interaction in Man. Nortriptyline and Antipyrine,” <i>Pharmacology</i>, 1975, 1(2)3:101-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=49899\">[PubMed 49899]</a></p>\n<p>3. Pond SM, Graham GG, Birkett DJ, et al, “Effects of Tricyclic Antidepressants on Drug Metabolism,” <i>Clin Pharmacol Ther</i>, 1975, 18(2):191-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=50160\">[PubMed 50160]</a></p>\n<p>4. Koch-Weser J, “Haemorrhagic Reactions and Drug Interactions in 500 Warfarin-Treated Patients,” <i>Clin Pharmacol Ther</i>, 1973, 14:139.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2872":"<p><b>Title</b> Calcium Channel Blockers / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Calcium Channel Blockers. <b>Severity</b> Minor <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine*, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine*, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine*, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil*</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin*, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A mild increase in blood pressure occurred in 12 amlodipine-treated patients following 3 days of ibuprofen therapy (400 mg 3 times/day).<sup>1</sup> Studies evaluating the effects of indomethacin on the efficacy of nifedipine, felodipine, and verapamil revealed no such effects.<sup>2,3,4</sup> The antihypertensive effects of amlodipine were unaffected in 24 patients who received a concomitant 3-week course of indomethacin (50 mg twice daily).<sup>5</sup> The mechanism for this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Minuz P, Pancera P, Ribul M, et al, “Amlodipine and Haemodynamic Effects of Cyclo-Oxygenase Inhibition,” <i>Br J Clin Pharmacol</i>, 1995, 39(1):45-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7756098\">[PubMed 7756098]</a></p>\n<p>2. Salvetti A, Pedrinelli R, Magagna A, et al, “Calcium Antagonists: Interactions in Hypertension,” <i>Am J Nephrol</i>, 1986, 6(Suppl 1):95-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3548365\">[PubMed 3548365]</a></p>\n<p>3. Hardy BG, Bartle WR, Myers M, et al, “Effect of Indomethacin on Pharmacokinetics and Pharmacodynamics of Felodipine,” <i>Br J Clin Pharmacol</i>, 1988, 26(5):557-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3207560\">[PubMed 3207560]</a></p>\n<p>4. Houston MC, Weir M, Gray J, et al, “The Effects of Nonsteroidal Anti-Inflammatory Drugs on Blood Pressures of Patients With Hypertension Controlled by Verapamil,” <i>Arch Intern Med</i>, 1995, 155(10):1049-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7748048\">[PubMed 7748048]</a></p>\n<p>5. Morgan TO, Anderson A, and Bertram D, “Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,” <i>Am J Hypertens</i>, 2000, 13(11):1161-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11078175\">[PubMed 11078175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2874":"<p><b>Title</b> Opioid Analgesics / Ammonium Chloride</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ammonium Chloride may increase the excretion of Opioid Analgesics. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of narcotic analgesics if ammonium chloride is initiated/dose increased, or increased effects if ammonium chloride is discontinued/dose decreased.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone*, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Methadone, as a weak base, will exist more in an ionized (nonreabsorbable) form in acidic urine, such as that produced by ammonium chloride.<sup>1,2</sup> The ability of ammonium chloride coadministration to affect the clinical outcome of methadone administration is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Baselt RC and Casarett LJ, “Urinary Excretion of Methadone in Man,” <i>Clin Pharmacol Ther</i>, 1972, 13(1):64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5008192\">[PubMed 5008192]</a></p>\n<p>2. Bellward GD, Warren PM, Howald W, et al, “Methadone Maintenance: Effect of Urinary pH on Renal Clearance in Chronic High and Low Doses,” <i>Clin Pharmacol Ther</i>, 1977, 22(1):92-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17500\">[PubMed 17500]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2876":"<p><b>Title</b> Ammonium Chloride / Potassium-Sparing Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of metabolic acidosis during concomitant therapy with ammonium chloride and a potassium-sparing diuretic.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone*, Triamterene</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A study in 4 normal subjects demonstrated the ability of spironolactone to inhibit ammonium chloride-induced urinary acidification.<sup>1</sup> A case report describes the development of metabolic acidosis associated with coadministration of ammonium chloride, potassium chloride, and spironolactone.<sup>2</sup> The mechanism(s) of this potential interaction is unknown. Possible mechanisms might be related to the ability of spironolactone to impair H+ ion excretion by the kidney due to aldosterone inhibition, and the subsequent systemic accumulation of excess H+ ions contributed by the ammonium chloride.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Manuel MA, Beirne GJ, Wagnild JP, et al, “An Effect of Spironolactone on Urinary Acidification in Normal Man,” <i>Arch Intern Med</i>, 1974, 134(3):472-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4850527\">[PubMed 4850527]</a></p>\n<p>2. Mashford ML and Robertson MB, “Spironolactone and Ammonium and Potassium Chloride,” <i>Br Med J</i>, 1972, 4(835):298-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5083905\">[PubMed 5083905]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2877":"<p><b>Title</b> Barbiturates / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may decrease the metabolism of Barbiturates. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of barbiturates if a monoamine oxidase inhibitor (MAOI) is initiated/dose increased, or decreased effects if MAOI is discontinued/dose decreased. In general, furazolidone, linezolid, and procarbazine will pose less risk than isocarboxazid, phenelzine, or tranylcypromine. Caution is still advised. Selegiline administered in high oral dosages (eg, &gt;10 mg daily of tablet/capsule; &gt; 2.5 mg daily of orally disintegrating tablet) or transdermally will exhibit nonselective MAOI activity.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital*, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A case report describes a tranylcypromine-stable patient (30 mg/day for 3 weeks) who became semicomatose following the administration of a single IM dose of amobarbital (250 mg).<sup>1</sup> The condition lasted more than 24 hours. The mechanism of this presumed interaction might be related to a decrease in barbiturate metabolism induced by the monoamine oxidase inhibitor.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Domino EF, Sullivan TS, and Luby ED, “Barbiturate Intoxication in Patient Treated With a MAO Inhibitor,” <i>Am J Psychiatry</i>, 1962, 118:941-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13887126\">[PubMed 13887126]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2878":"<p><b>Title</b> Halofantrine / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Halofantrine. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide*, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 7 healthy volunteers, magnesium carbonate (1,000 mg) decreased the halofantrine (500 mg single dose) AUC 28%.<sup>1</sup> The clinical importance of this interaction is unknown. The mechanism is likely related to binding of halofantrine to the antacid in the GI tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aideloje SO, Onyeji CO, Ugwu NC. Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate. <i>Eur J Pharm Biopharm</i>. 1998;46(3):299-303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9885302\">[PubMed 9885302]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2879":"<p><b>Title</b> Salicylates / Ginkgo Biloba</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ginkgo Biloba may enhance the anticoagulant effect of Salicylates. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> One published case report describes an elderly man who experienced spontaneous bleeding in the anterior chamber of the eye while taking concomitant aspirin (325 mg orally daily) and ginkgo biloba extract.<sup>1</sup> No additional events occurred during the 3 months following the discontinuation of ginkgo (aspirin was continued). A second case report describes persistent postoperative bloody/serous wound discharge in a 77 year old woman receiving aspirin and ginkgo biloba extract.<sup>2</sup> The discharge continued for 10 days before aspirin was discontinued, then another 3 weeks before ginkgo was discontinued, then for approximately an additional 6 weeks before remitting fully. No coagulation abnormalities were detected prior to ginkgo discontinuation.<br><br>Three clinical studies have been conducted assessing possible platelet inhibitory effects of ginkgo biloba. A study of 50 healthy volunteers showed no additional increase in bleeding time or induced platelet aggregation when ginkgo biloba extract (EGb 761 120 mg orally daily, Dr. Willman Schwabe Pharmaceuticals, Karlsruhe, Germany) was added to aspirin (500 mg orally daily).<sup>3</sup> A study of 60 patients (mean age 69 +/- 10 years) receiving aspirin (325 mg orally daily) showed no increase in induced platelet aggregation in patients randomly assigned to receive EGb 761 (300 mg orally daily).<sup>4</sup> A study of 10 healthy volunteers showed no significant impact of a ginkgo biloba supplement (regimen not specified, General Nutrition Center, Columbia, Missouri) on induced platelet aggregation.<sup>5</sup><br><br>The mechanism of the proposed interaction between ginkgo and salicylates is unclear. A connection between ginkgo biloba supplementation and bleeding episodes, some serious, has been proposed in a number of case reports.<sup>6,7,8,9,10,11,12,13</sup> While antiplatelet effects appear to be unlikely based on the above studies, a lack of product uniformity precludes any generalized conclusions, even those concerning the specific products tested.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Rosenblatt M and Mindel J, “Spontaneous Hyphema Associated With Ingestion of Ginkgo Biloba Extract,” <i>N Engl J Med</i>, 1997, 336(15):1108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9091822\">[PubMed 9091822]</a></p>\n<p>2. Bebbington A, Kulkarni R and Roberts P, “Ginkgo Biloba: Persistent Bleeding After Total Hip Arthroplasty Caused by Herbal Self-Medication,” <i>J Arthroplasty</i>, 2005, 20(1):125-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15660071\">[PubMed 15660071]</a></p>\n<p>3. Wolf HR, “Does Ginkgo Biloba Special Extract EGb 761 Provide Additional Effects on Coagulation and Bleeding When Added to Acetylsalicylic Acid 500 mg Daily?” <i>Drugs R D</i>, 2006, 7(3):163-72. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16752942\">[PubMed 16752942]</a></p>\n<p>4. Gardner CD, Zehnder JL, Rigby AJ, et al, “Effect of Ginkgo Biloba (EGb 761) and Aspirin on Platelet Aggregation and Platelet Function Analysis Among Older Adults at Risk of Cardiovascular Disease: A Randomized Clinical Trial,” <i>Blood Coagul Fibrinolysis</i>, 2007, 18(8):787-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17982321\">[PubMed 17982321]</a></p>\n<p>5. Beckert BW, Concannon MJ, Henry SL, et al, “The Effect of Herbal Medicines on Platelet Function: An In Vivo Experiment and Review of the Literature,” <i>Plast Reconstr Surg</i>, 2007, 120(7):2044-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18090773\">[PubMed 18090773]</a></p>\n<p>6. Rowin J and Lewis SL, “Spontaneous Bilateral Subdural Hematomas Associated With Chronic Ginkgo Biloba Ingestion,” <i>Neurology</i>, 1996, 46(6):1775-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8649594\">[PubMed 8649594]</a></p>\n<p>7. Vale S, “Subarachnoid Haemorrhage Associated With Ginkgo Biloba,” <i>Lancet</i>, 1998, 352(9121):36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9800751\">[PubMed 9800751]</a></p>\n<p>8. Matthews MK Jr, “Association of Ginkgo Biloba With Intracerebral Hemorrhage,” <i>Neurology</i>, 1998, 50(6):1933-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9633781\">[PubMed 9633781]</a></p>\n<p>9. Gilbert GJ, “Ginkgo Biloba,” <i>Neurology</i>, 1997, 48(4):1137. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9109922\">[PubMed 9109922]</a></p>\n<p>10. Fessenden JM, Wittenborn W and Clarke L, “Gingko Biloba: A Case Report of Herbal Medicine and Bleeding Postoperatively From a Laparoscopic Cholecystectomy,” <i>Am Surg</i>, 2001, 67(1):33-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11206893\">[PubMed 11206893]</a></p>\n<p>11. Rosenblatt M and Mindel J, “Spontaneous Hyphema Associated With Ingestion of Ginkgo Biloba Extract,” <i>N Engl J Med</i>, 1997, 336(15):1108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9091822\">[PubMed 9091822]</a></p>\n<p>12. Benjamin J, Muir T, Briggs K, et al, “A Case of Cerebral Haemorrhage-Can Ginkgo Biloba be Implicated?” <i>Postgrad Med J</i>, 2001, 77(904):112-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11161079\">[PubMed 11161079]</a></p>\n<p>13. Jayasekera N, Moghal A, Kashif F, et al, “Herbal Medicines and Postoperative Haemorrhage,” <i>Anaesthesia</i>, 2005, 60(7):725-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15960738\">[PubMed 15960738]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2880":"<p><b>Title</b> Vitamin K Antagonists / Ginkgo Biloba</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ginkgo Biloba may enhance the adverse/toxic effect of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider avoiding the use of this combination of agents. Monitor for signs and symptoms of bleeding if vitamin K antagonists and Ginkgo biloba are used concomitantly.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> One case report describes an elderly woman who experienced an apparently spontaneous left parietal hemorrhage while taking concomitant warfarin and ginkgo for approximately 2 months.<sup>1</sup> <br><br>In a clinical study of 12 healthy volunteers, Tavonin (Ginkgo biloba standardized dry extract, EGb761, equivalent to 2 g of Ginkgo biloba leaf, 9.6 mg of ginkgo flavonglycosides, 2.4 mg of ginkgolides and bilobalide, Dr Willmar Schwabe GmbH &amp; Co. Germany) 2 tablets three times daily for a week prior to a single 25 mg oral warfarin dose had no significant impact on warfarin pharmacokinetic parameters, INR, or platelet aggregation.<sup>2</sup> In a brief report of a crossover study of 24 patients receiving long-term warfarin treatment, ginkgo (Bio-Biloba, Pharma Nord ApS Denmark, 100 mg daily for 4 weeks) had no impact on INR or steady state warfarin dose.<sup>3</sup> <br><br>The proposed mechanism of this interaction is ginkgo inhibition of platelet aggregation increasing the risk of bleeding during treatment with vitamin K antagonists. Ginkgo has been associated with bleeding, including intracerebral hemorrhage, when used alone.<sup>4,5,6,7,8</sup> However, in a mouse study, both ginkgo biloba extract (GBE) and ginkgolide B failed to demonstrate any effect on coagulation parameters.<sup>9</sup> Further, GBE actually diminished the anticoagulant effect of warfarin, and appeared to increase the metabolism of warfarin, an effect that the authors attributed to bilobalide, one of the GBE components with demonstrated enzyme inducing potential. In contrast with this latter finding/conclusion, a previous study in healthy volunteers found that ginkgo does not appear to affect warfarin pharmacokinetics.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Matthews MK Jr, “Association of Ginkgo Biloba With Intracerebral Hemorrhage,” <i>Neurology</i>, 1998, 50(6):1933-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9633781\">[PubMed 9633781]</a></p>\n<p>2. Jiang X, Williams KM, Liauw WS, et al, “Effect of Ginkgo and Ginger on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects,” <i>Br J Clin Pharmacol</i>, 2005, 59(4):425-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15801937\">[PubMed 15801937]</a></p>\n<p>3. Engelsen J, Nielsen JD and Winther K, “Effect of Coenzyme Q10 and Ginkgo Biloba on Warfarin Dosage in Stable, Long-Term Warfarin Treated Outpatients. A Randomised, Double Blind, Placebo-Crossover Trial,” <i>Thromb Haemost</i>, 2002, 87(6):1075-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12083489\">[PubMed 12083489]</a></p>\n<p>4. Odawara M, Tamaoka A, and Yamashita K, “Ginkgo Biloba,” <i>Neurology</i>, 1997, 48(3):789-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9065574\">[PubMed 9065574]</a></p>\n<p>5. Skogh M, “Extracts of Ginkgo Biloba, and Bleeding or Haemorrhage,” <i>Lancet</i>, 1998, 352(9134):1145-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9798614\">[PubMed 9798614]</a></p>\n<p>6. Vale S, “Subarachnoid Haemorrhage Associated With Ginkgo Biloba,” <i>Lancet</i>, 1998, 352(9121):36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9800751\">[PubMed 9800751]</a></p>\n<p>7. Rosenblatt M and Mindel J, “Spontaneous Hyphema Associated With Ingestion of Ginkgo Biloba Extract,” <i>N Engl J Med</i>, 1997, 336(15):1108. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9091822\">[PubMed 9091822]</a></p>\n<p>8. Benjamin J, Muir T, Briggs K, et al, “A Case of Cerebral Haemorrhage-Can Ginkgo Biloba be Implicated?” <i>Postgrad Med</i>, 2001, 77(904):112-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11161079\">[PubMed 11161079]</a></p>\n<p>9. Taki Y, Yokotani K, Yamada S, et al, “Ginkgo Biloba Extract Attenuates Warfarin-Mediated Anticoagulation Through Induction of Hepatic Cytochrome P450 Enzymes by Bilobalide in Mice,” <i>Phytomedicine</i>, 2011, Jul 28 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21802929\">[PubMed 21802929]</a></p>\n<p>10. Jiang X, Blair EY, McLachlan AJ, “Investigation of the Effects of Herbal Medicines of Warfarin Response in Healthy Subjects: A Population Pharmacokinetic-pharmacodynamic Modeling Approach,” <i>J Clin Pharmacol</i>, 2006, 46(11):1370-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17050802\">[PubMed 17050802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2881":"<p><b>Title</b> Salicylates / Griseofulvin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Griseofulvin may decrease the serum concentration of Salicylates. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of salicylates if griseofulvin is initiated/dose increased, or increased effects if griseofulvin is discontinued/dose decreased.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Case report. An 8-year-old boy, stable on aspirin therapy (147 mg/kg/day; serum concentration = 30.6 mg/dL 5.5 hours after last dose) experienced a significant reduction in serum aspirin concentrations (&lt;0.2 mg/dL) within 2 days of starting griseofulvin therapy.<sup>1</sup> Of note, the aspirin dose was reduced to 100 mg/kg/day at the time of griseofulvin initiation. Within 2 days of discontinuing griseofulvin, the patient showed significant recovery (16.9 mg/dL 9.5 hours after aspirin dose). The mechanism of this presumed interaction is unknown, but might be related to reduced aspirin absorption, or increased aspirin metabolism due to griseofulvin induction of CYP2C8/9 isoenzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phillips KR, Wideman SD, Cochran EB, et al, “Griseofulvin Significantly Decreases Serum Salicylate Concentrations,” <i>Ped Infect Dis J</i>, 1993, 12(3):350-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8483633\">[PubMed 8483633]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2882":"<p><b>Title</b> Methotrexate / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Due to the severity of this potential interaction, consider avoiding the concomitant use of salicylates (and other nonsteroidal anti-inflammatory agents) and methotrexate (especially if methotrexate is being used in higher doses as in the treatment of neoplastic disorders). If salicylates and methotrexate are used concomitantly, monitor for increased toxic effects of the methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid*, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate*, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Serum concentrations, and associated toxicity, of methotrexate appear to be increased by concomitant salicylate administration. The effect of salicylates on single doses of methotrexate (10 mg) is relatively small (increase AUC 28%; decrease clearance 16%).<sup>1</sup> Similar effects are seen with aminosalicylate sodium and choline magnesium trisalicylate.<sup>2,3</sup> Higher doses of methotrexate (eg, 50 mg/day for 10 days) administered with salicylates have resulted in lethal pancytopenia.<sup>4</sup> The severity of the interaction appears to worsen with increasing doses of methotrexate and/or salicylates. The mechanism(s) of these interactions might be multifold. Salicylates might compete with methotrexate for renal tubular secretion. Due to their inhibition of prostaglandin synthesis, salicylates might also reduce renal perfusion, and subsequently reduce methotrexate elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Stewart CF, Fleming RA, Germain BF, et al, “Aspirin Alters Methotrexate Disposition in Rheumatoid Arthritis Patients,” <i>Arthritis Rheum</i>, 1991, 34(12):1514-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1747136\">[PubMed 1747136]</a></p>\n<p>2. Maier WP, Leon-Perez R, and Miller SB, “Pneumonitis During Low-Dose Methotrexate Therapy,” <i>Arch Intern Med</i>, 1986, 146(3):602-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3954536\">[PubMed 3954536]</a></p>\n<p>3. Tracy TS, Jones DR, Hall SD, et al, “The Effect of NSAIDs on Methotrexate Disposition in Patients With Rheumatoid Arthritis,” <i>Clin Pharmacol Ther</i>, 1990, 47:138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1618240\">[PubMed 1618240]</a></p>\n<p>4. Mandel MA, “The Synergistic Effect of Salicylates on Methotrexate Toxicity,” <i>Plast Reconstr Surg</i>, 1976, 57(6):733-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1273152\">[PubMed 1273152]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2883":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of angiotensin-converting enzyme inhibitors if combined with a salicylate. Additionally, monitor for acute renal failure when these agents are combined.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril*, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Numerous studies have suggested that the addition of aspirin may result in reduced efficacy of angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure.<sup>1,2,3,4,5,6,7,8,9,10,11,12</sup> Some studies have suggested that aspirin attenuates the beneficial acute hemodynamic effects of ACE inhibitors,<sup>3,4,5,6,7,9</sup> while some have suggested that aspirin may negate ACE inhibitor induced arterial vasodilation.<sup>8,10,12</sup> An increase in hospitalization and mortality rates with the combination of aspirin and an ACE inhibitors has been reported in some studies as well.<sup>1,2,11</sup> The majority of these studies report an interaction between ACE inhibitors and aspirin when aspirin is given at low cardioprotective doses (no more than 350 mg per day).<sup>1,2,3,4,5,6,7,8,9,12</sup> However, one study reported that the combination of aspirin and an ACE inhibitors was associated with increased mortality when the aspirin dose was greater than 325 mg per day, while no increase in mortality was seen with aspirin doses less than 160 mg per day.<sup>11</sup> <br><br>Other studies reported that aspirin may decrease the antihypertensive effects of ACE inhibitors.<sup>13,14,15</sup> In two studies, aspirin 300 mg once daily resulted in a decreased blood pressure lowering effect of enalapril, while aspirin 100 mg once daily had no effect.<sup>14,15</sup> The antihypertensive effect of captopril was also blunted when co-administered with aspirin 600 mg four times daily.<sup>13</sup><br><br>The combination of aspirin and ACE inhibitors may also result in decreased kidney function.<sup>16,17,18</sup> One retrospective analysis of patients with heart failure found that the decrease in glomerular filtration rate was greater in those who received an ACE inhibitor and aspirin (100 mg to 1,000 mg daily) compared with those who received an ACE inhibitor alone.<sup>18</sup> Other reports described decreases in renal function associated with the concomitant use of ACE inhibitors and high-dose aspirin.<sup>16,17</sup> <br><br>In contrast, a multitude of studies have suggested that aspirin and ACE inhibitors can be safely combined.<sup>19,20,21,22,,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39</sup> In patients with heart failure, various studies reported that aspirin therapy failed to alter the acute hemodynamic or vasodilatory effects of ACE inhibitors,<sup>24,25,26,27</sup> and that the combination of aspirin and an ACE inhibitor was not associated with an increased risk of hospitalization or mortality.<sup>19,20,21,22,27,28</sup> Further studies report that aspirin does not interfere with the antihypertensive effects of ACE inhibitors,<sup>33,34,35,36</sup> and that the combination of aspirin and an ACE inhibitor does not lead to an increased risk of kidney damage.<sup>29,30,31,32</sup> Additionally, in two large retrospective analyses, the addition of aspirin to ACE inhibitor therapy failed to reduce the benefits of ACE inhibitor therapy or increase the incidence of major cardiovascular adverse events.<sup>38,39</sup> Lastly, in a pharmacokinetic study, the concomitant administration of aspirin (325 mg single dose) and benazepril (20 mg single dose) had no effect on the pharmacokinetic parameters of either drug.<sup>37</sup><br><br>ACE inhibitors stimulate the synthesis of prostaglandins and results in vasodilation of systemic vessels and renal efferent arterioles. In direct opposition to the effect of ACE inhibitors, salicylates inhibit prostaglandin formation. Thus, they may attenuate the beneficial systemic vasodilatory effects of ACE inhibitors in the treatment of heart failure or hypertension.<sup>40,41</sup> Additionally, prostaglandin inhibition by salicylates leads to renal afferent arteriole vasoconstriction, and when combined with ACE inhibitor induced renal efferent arteriole vasodilation, may lead to a decrease in glomerular filtration rate and kidney injury.<sup>42</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). <i>Am J Cardiol</i>. 1997:79(2):115-119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9193008\">[PubMed 9193008]</a></p>\n<p>2. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. <i>J Am Coll Cardiol</i>. 1998:31(2):419-425. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9462588\">[PubMed 9462588]</a></p>\n<p>3. Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. <i>Circulation</i>. 1997:95(7):1930-1936. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9107182\">[PubMed 9107182]</a></p>\n<p>4. Viecili PR, Pamplona D, Park M, Silva SR, Ramires JA, Da Luz PL. Antagonism of the acute hemodynamic effects of captopril in decompensated congestive heart failure by aspirin administration. <i>Braz J Med Biol Res</i>. 2003:36(6):771-780 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12792707\">[PubMed 12792707]</a></p>\n<p>5. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. <i>Circulation</i>. 1998;98(8):757-765. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727545\">[PubMed 9727545]</a></p>\n<p>6. Guazzi M, Pontone G, Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. <i>Am Heart J</i>. 1999:138(2 pt 1):254-260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10426836\">[PubMed 10426836]</a></p>\n<p>7. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. <i>J Am Coll Cardiol</i>. 1992:20(7):1549-1555. [PubMed1452929]</p>\n<p>8. Galatius S, Wroblewski H, Kastrup J. Does aspirin treatment influence vascular resistance and fluid filtration in patients with congestive heart failure? <i>Heart</i>. 1999:81(3):330. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10357590\">[PubMed 10357590]</a></p>\n<p>9. Meune C, Wahbi K, Fulla Y, et al. Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors. <i>Eur J Heart Fail</i>. 2007:9(2):197-201. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16914369\">[PubMed 16914369]</a></p>\n<p>10. Meune C, Mahe I, Mourad JJ, et al. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. <i>Eur J Heart Fail</i>. 2003:5(3):271-279. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12798824\">[PubMed 12798824]</a></p>\n<p>11. Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. <i>Arch Intern Med</i>. 2003:163(13):1574-1579. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12860580\">[PubMed 12860580]</a></p>\n<p>12. MacIntrye IM, Jhund PS, McMurray JJ. Aspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failure. <i>Cardiovasc Drugs Ther</i>. 2005:19(4):261-265. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16187007\">[PubMed 16187007]</a></p>\n<p>13. Moore TJ, Crantz FR, Hollenberg NK, et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. <i>Hypertension</i>. 1981:3(2):168-173. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6260645\">[PubMed 6260645]</a></p>\n<p>14. Alimento M, Campodonico J, Santambrogio G, et al. The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors. <i>Cardiologia</i>. 1997:42(6):605-610. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9289376\">[PubMed 9289376]</a></p>\n<p>15. Guazzi MD, Campodonico J, Celeste F, et al. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. <i>Clin Pharmacol Ther</i>. 1998:63(1):79-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9465844\">[PubMed 9465844]</a></p>\n<p>16. Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure. <i>Am J Med</i>. 1991:90(5):571-575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2029014\">[PubMed 2029014]</a></p>\n<p>17. Seelig CB, Maloley PA, Campbell JR. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. <i>South Med J</i>. 1990:83(10):1144-1148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2218652\">[PubMed 2218652]</a></p>\n<p>18. Dietz R, Nagel F, Osterziel KJ. Angiotensin-converting enzyme inhibitors and renal function in heart failure. <i>Am J Cardiol</i>. 1992:70(10):119C-125C. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1329467\">[PubMed 1329467]</a></p>\n<p>19. Pedone C, Cecchi E, Matucci R, et al. GIFA Investigators. Does aspirin attenuate the beneficial effect of ACE inhibitors in elderly people with heart failure? <i>Drugs Aging</i>. 2005:22(7):605-614. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16491523\">[PubMed 16491523]</a></p>\n<p>20. Lapane KL, Hume AL, Barbour MM, Lipsitz LA. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure? <i>J Am Geriatr Soc</i>. 2002:50(7):1198-1204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12133013\">[PubMed 12133013]</a></p>\n<p>21. McAlister FA, Ghali WA, Gong Y, Fang J, Armstrong PW, Tu JV. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. <i>Circulation</i>. 2006:113(22):2572-2578. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16735672\">[PubMed 16735672]</a></p>\n<p>22. Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. <i>J Am Coll Cardiol</i>. 1999:33(7):1920-1925. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10362194\">[PubMed 10362194]</a></p>\n<p>23. Oosterga M, Anthonio RL, de Kam PJ, Kingma JH, Crijns HJ, van Gilst WH. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. <i>Am J Cardiol</i>. 1998:81(10):1178-1181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9604941\">[PubMed 9604941]</a></p>\n<p>24. Baur LH, Schipperheyn JJ, van der Laarse A, et al, Combining salicylate and enalapril in patients with coronary artery disease and heart failure. <i>Br Heart J</i>. 1995:73(3):227-236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7727181\">[PubMed 7727181]</a></p>\n<p>25. van Wijngaarden J, Smit AJ, de Graeff PA, et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. <i>J Cardiovasc Pharmacol</i>. 1994:23(2):240-245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7511753\">[PubMed 7511753]</a></p>\n<p>26. Katz SD, Radin M, Graves T, Hauck C, Block A, LeJemtel TH. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with Enalapril. Ifetroban Study Group. <i>J Am Coll Cardiol</i>. 1999:34(1):170-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10400007\">[PubMed 10400007]</a></p>\n<p>27. Harjai KJ, Solis S, Prasad A, Loupe J. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. <i>Int J Cardiol</i>. 2003:88(2-3):207-214. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12714200\">[PubMed 12714200]</a></p>\n<p>28. Aumegeat V, Lamblin N, de Groote P, et al. Aspirin does not adversely affect survival in patients with stable congestive heart failure treated with Angiotensin-converting enzyme inhibitors. <i>Chest</i>. 2003:124(4):1250-1258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14555553\">[PubMed 14555553]</a></p>\n<p>29. Juhlin T, Bjorkman S, Gunnarsson B, Fyge A, Roth B, Hoglund P. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. <i>Eur J Heart Fail</i>. 2004:6(7):909-916. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15556053\">[PubMed 15556053]</a></p>\n<p>30. Camargo EG, Weinert LS, Lavinsky J, Gross JL, Silveiro SP. The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. <i>Diabetes Care</i>. 2007:30(7):66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17596489\">[PubMed 17596489]</a></p>\n<p>31. Bouvy ML, Heerdink ER, Hoes AW, Leufkens HG. Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors. <i>Drug Saf</i>. 2003:26(13):983-989.<a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14583072\">[PubMed 14583072]</a></p>\n<p>32. Schwartz D, Kornowski R, Lehrman H, et al. Combined effect of captopril and aspirin in renal hemodynamics in elderly patients with congestive heart failure. <i>Cardiology</i>. 1992:81(6):334-339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1304414\">[PubMed 1304414]</a></p>\n<p>33. Zanchetti A, Hansson L, Leonetti G, et al. Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. <i>J Hypertens</i>. 2002:20(5):1015-1022. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12011664\">[PubMed 12011664]</a></p>\n<p>34. Polonia J, Boaventura I, Gama G, et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. <i>J Hypertens</i>. 1995:13(8):925-931. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8557971\">[PubMed 8557971]</a></p>\n<p>35. Boger RH, Bode-Boger SM, Kramme P, Tsikas D, Gutzki FM, Frolich JC. Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. <i>Br J Clin Pharmacol</i>. 1996:42(6):721-727. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8971427\">[PubMed 8971427]</a></p>\n<p>36. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA. Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. <i>Am J Hypertens</i>. 1999:12(8 pt 1):784-789. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10480471\">[PubMed 10480471]</a></p>\n<p>37. Sioufi A, Pommier F, Gauducheau N, Godbillon J, Choi L, John V. The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers. <i>Biopharm Drug Dispos</i>. 1994:15(6):451-461. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7993983\">[PubMed 7993983]</a></p>\n<p>38. Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. <i>Lancet</i>. 2002:360(9339):1037-1043. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12383982\">[PubMed 12383982]</a></p>\n<p>39. Latini R, Santoro E, Masson S, et al; GISSI-3 Investigators. Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial. <i>Heart Dis</i>. 2000:2(3):185-190. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11728260\">[PubMed 11728260]</a></p>\n<p>40. van Wijngaarden J, Tio RA, van Gilst WH, de Graeff PA, de Langen CD. Wesseling H. Basic pharmacology of ACE-inhibitors with respect to ischaemic heart disease: prostaglandins and bradykinin. <i>Eur Heart J</i>. 1990:11(suppl B):84-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2194812\">[PubMed 2194812]</a></p>\n<p>41. Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. <i>J Clin Invest</i>. 1978:61(2):314-319. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=413839\">[PubMed 413839]</a></p>\n<p>42. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. <i>Annu Rev Pharmacol Toxicol</i>. 1993;33(1):435-465. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8494347\">[PubMed 8494347]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2885":"<p><b>Title</b> Cardiac Glycosides / Amphotericin B</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased toxic effects of cardiac glycosides and monitor serum potassium levels if amphotericin B is used with a cardiac glycoside.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional)*, Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The risk of digitalis toxicity increases in the presence of hypokalemia and digoxin prescribing information recommends careful monitoring of serum potassium levels when digoxin is given to patients at risk for hypokalemia.<sup>1</sup> Prescribing information for amphotericin B warns that hypokalemia is a common adverse event (incidence 37% to 55%), which may potentiate digitalis toxicity thus warranting close monitoring of serum potassium levels during combined use.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Digoxin [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2012.</p>\n<p>2. <i>Ambisome</i> (amphotericin B) [prescribing information]. San Dimas, CA: Gilead Sciences Inc; March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2886":"<p><b>Title</b> Aminoglycosides / Amphotericin B</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased nephrotoxic effects of aminoglycosides if amphotericin B is initiated or the dose is increased. Newer amphotericin formulations (ie, lipid complex, liposomal, cholesteryl sulfate complex) should be safer options than the conventional amphotericin formulation.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional)*, Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> The addition of amphotericin B to 4 patients already receiving gentamicin resulted in renal toxicity.<sup>1</sup> Both agents possess the potential to cause nephrotoxicity. Whether the effects noted in these patients were due to synergism, additive toxicity or another mechanism is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Churchill DN and Seely J, “Nephrotoxicity Associated With Combined Gentamicin-Amphotericin B Therapy,” <i>Nephron</i>, 1977, 19(3):176-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=268496\">[PubMed 268496]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2887":"<p><b>Title</b> Neuromuscular-Blocking Agents / Amphotericin B</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Amphotericin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required beyond the routine serum potassium monitoring that accompanies the use of amphotericin B.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n <p><b>Neuromuscular-Blocking Agents Interacting Members</b> Atracurium, Cisatracurium, Mivacurium, Pancuronium, Rocuronium, Succinylcholine, Vecuronium</p>\n</div> \n<p><b>Discussion</b> Amphotericin B prescribing information states that because amphotericin B use can result in clinically significant hypokalemia, enhanced/prolonged muscle relaxation may occur in patients receiving neuromuscular-blocking agents.<sup>1</sup> Monitor serum potassium levels closely.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ambisome (amphotericin B liposome) [prescribing information]. San Dimas, CA: Gilead Sciences Inc; March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2888":"<p><b>Title</b> Vitamin K Antagonists / Salicylates</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Low cardioprotective aspirin doses, when indicated, generally only require enhanced monitoring for bleeding in patients receiving warfarin. Higher aspirin doses, and other salicylates included in this monograph, should generally be avoided.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Patients receiving coumarin derivatives should not take salicylate-containing medicines on an as-needed basis. Nonacetylated salicylates might be safer than aspirin. Acetaminophen (&lt;1.3 g/day for &lt;1 week) may be an acceptable antipyretic and analgesic choice for patients taking coumarin derivatives; caution appears warranted with higher acetaminophen doses. Aspirin (80-325 mg/day) and warfarin are used together, in selected cases and with careful monitoring, for the prevention of cardiovascular events. Monitor for increased signs and symptoms of bleeding whenever a coumarin derivative and a salicylate are used concomitantly.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Sodium Salicylate, Triflusal<br><b>Exception</b> Salsalate</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concomitant therapy with aspirin and oral anticoagulants has been shown to significantly increase the risk of bleeding, both major and minor.<sup>1</sup> In a 534-patient study excessive bleeding (requiring blood transfusion or hospitalization) was three times higher in those receiving warfarin and aspirin (500 mg/day), than in those receiving warfarin and dipyridamole (400 mg/day) or warfarin alone.<sup>2</sup> Bleeding events primarily involved the gastrointestinal tract or central nervous system (all patients who experienced cerebral bleeds died). Other reports provide similar data.<sup>3,4,5,6</sup> Though the risk of bleeding, especially gastrointestinal, is increased by even small doses of aspirin, a study using daily 3 g doses failed to show any effect on the INR in warfarin-treated patients.<sup>7</sup> This supports the prevailing thought of the involvement of multiple mechanisms associated with these interactions. In small doses, aspirin can inhibit platelet function and cause gastric erosion. In larger doses, aspirin can exhibit a hypoprothrombinemic response that is likely additive with that of the coumarin derivative.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hylek EM, Heiman H, Skates SJ, et al, “Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,” <i>JAMA</i>, 1998, 279(9):657-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9496982\">[PubMed 9496982]</a></p>\n<p>2. Chesebro JH, Fuster V, Elveback LR, et al, “Trial of Combined Warfarin Plus Dipyridamole or Aspirin Therapy in Prosthetic Heart Valve Replacement: Danger of Aspirin Compared With Dipyridamole,” <i>Am J Cardiol</i>, 1983, 51(9):1537-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6342354\">[PubMed 6342354]</a></p>\n<p>3. Altman R, Buollon F, Rouvier J, et al, “Aspirin and Prophylaxis of Thromboembolic Complications in Patients With Substitute Heart Valves,” <i>J Thoracic Cardiovasc Surg</i>, 1976, 72(1):127-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1084448\">[PubMed 1084448]</a></p>\n<p>4. Dale J, Myhre E, Storstein O, et al, “Prevention of Arterial Thromboembolism With Acetylsalicylic Acid: A Controlled Clinical Study in Patients With Aortic Ball Valves,” <i>Am Heart J</i>, 1977, 94(1):101-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=326013\">[PubMed 326013]</a></p>\n<p>5. Dale J, Myhre E, and Loew D, “Bleeding During Acetylsalicylic Acid and Anticoagulant Therapy in Patients With Reduced Platelet Reactivity After Aortic Valve Replacement,” <i>Am Heart J</i>, 1980, 99(6):746-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6966467\">[PubMed 6966467]</a></p>\n<p>6. Younossi ZM, Strum WB, Schatz RA, et al, “Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding,” <i>Dig Dis Sci</i>, 1997, 42(1):79-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9009119\">[PubMed 9009119]</a></p>\n<p>7. Udall JA, “Drug Interference With Warfarin Therapy,” <i>Am J Cardiol</i>, 1969, 23:143.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2889":"<p><b>Title</b> Leukotriene Receptor Antagonists / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Salicylates may increase the serum concentration of Leukotriene Receptor Antagonists. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Leukotriene Receptor Antagonists Interacting Members</b> Montelukast, Pranlukast, Zafirlukast*</p>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin*, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> According to zafirlukast prescribing information, mean zafirlukast concentrations were 45% higher when zafirlukast (40 mg/day) was given with aspirin (650 mg 4 times/day).<sup>1</sup> Both the mechanism and clinical significance of these findings are unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Accolate (zafirlukast). Wilmington, DE: Zeneca Pharmaceuticals LP, 08/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2890":"<p><b>Title</b> Beta-Blockers / Dipyridamole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dipyridamole may enhance the bradycardic effect of Beta-Blockers. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs of bradycardia if IV dipyridamole is administered to a patient on a beta-blocker. Ophthalmic beta-blockers are likely of little concern.</p>\n<div>\n <p><b>Beta-Blockers Interacting Members</b> Acebutolol, Arotinolol, Atenolol*, Betaxolol (Ophthalmic), Betaxolol (Systemic), Bisoprolol, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Esmolol, Labetalol, Metoprolol*, Nadolol*, Nebivolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Timolol (Ophthalmic), Timolol (Systemic)<br><b>Exceptions</b> Levobunolol, Metipranolol</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Rare cases of bradycardia, and even asystole, have been reported to occur following the administration of IV dipyridamole (for diagnostic procedure) in patients already receiving beta-blockers.<sup>1,2,3</sup> The cardiac effects were successfully treated with aminophylline and atropine (in one case of asystole). The mechanism of these interactions might simply be addition of the mutually-held negative chronotropic effects. Large scale case reviews of patients undergoing similar procedures (many of whom were receiving beta-blockers) failed to identify any reports of bradycardia or asystole.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Blumenthal MS and McCauley CS, “Cardiac Arrest During Dipyridamole Imaging,” <i>Chest</i>, 1988, 93(5):1103-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3359832\">[PubMed 3359832]</a></p>\n<p>2. Roach PJ, Magee MA, and Freedman SB, “Asystole and Bradycardia During Dipyridamole Stress Testing in Patients Receiving Beta-Blockers,” <i>Int J Cardiol</i>, 1993, 42(1):92-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7906680\">[PubMed 7906680]</a></p>\n<p>3. Picano E, Marini C, Pirelli M, et al, “Safety of Intravenous High-Dose Dipyridamole Echocardiography. The Echo-Persantine International Cooperative Study Group,” <i>Am J Cardiol</i>, 1992, 70(2):252-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1626516\">[PubMed 1626516]</a></p>\n<p>4. Ranhosky A and Kempthorne-Rawson J, Intravenous Dipyridamole Thallium Imaging Study Group, “The Safety of Intravenous Dipyridamole Thallium Myocardial Perfusion Imaging. Intravenous Dipyridamole Thallium Imaging Study Group,” <i>Circulation</i>, 1990, 81(4):1205-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2107985\">[PubMed 2107985]</a></p>\n<p>5. Zhu YY, Chung WS, Botvinick EH, et al, “Dipyridamole Perfusion Scintigraphy: The Experience With Its Application in One Hundred Seventy Patients With Known or Suspected Unstable Angina,” <i>Am Heart J</i>, 1991, 121(1 Pt 1):33-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1985375\">[PubMed 1985375]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2892":"<p><b>Title</b> Antipsychotic Agents (Phenothiazines) / Attapulgite</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Attapulgite may decrease the absorption of Antipsychotic Agents (Phenothiazines). <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of phenothiazines if attapulgite is administered concurrently. If decreased effects are noted, consider separating doses of agents by 2 or more hours in order to minimize potential adsorption of the phenothiazine onto the attapulgite.</p>\n<div>\n <p><b>Antipsychotic Agents (Phenothiazines) Interacting Members</b> ChlorproMAZINE, FluPHENAZine, Methotrimeprazine, Periciazine, Perphenazine, Pipotiazine, Prochlorperazine, Promazine, Thioridazine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> The absorption of single doses of promethazine (50 mg) was reduced by approximately 50% in a patient following concurrent administration of an attapulgite-pectin combination product.<sup>1</sup> The mechanism of this apparent interaction is likely related to adsorption of the phenothiazine onto attapulgite in the gut.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sorby DL and Liu G, “Effects of Adsorbents on Drug Absorption. II. Effect of an Antidiarrhea Mixture on Promazine Absorption,” <i>J Pharm Sci</i>, 1966, 55:504-10.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2893":"<p><b>Title</b> AzaTHIOprine / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased anemia and/or neutropenia during azathioprine therapy if an angiotensin-converting enzyme inhibitor is used in combination, particularly at higher doses.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril*, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concomitant use of the angiotensin-converting enzyme (ACE) inhibitor captopril and azathioprine has resulted in a number of case reports of leukopenia or neutropenia.<sup>1,2,3</sup> In one case, administration of the agents alone did not produce leukopenia, but leukopenia occurred upon rechallenge with concomitant therapy.<sup>1</sup> A case series similarly describes an unexpectedly large number of azathioprine-treated patients who developed significant anemia during concurrent treatment with an ACE inhibitor.<sup>4</sup><br><br>The exact mechanism of this potential interaction is unknown, but ACE and/or angiotensin II have been shown to participate in normal myelopoiesis and erythropoiesis,<sup>5,6</sup> offering evidence for a possible additive/synergisitic effect of ACE inhibitors and azathioprine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Anonymous, “Successful Low Dose Captopril Rechallenge Following Drug Induced Leukopenia,” <i>Lancet</i>, 1981, 1(8234):1362-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6113327\">[PubMed 6113327]</a></p>\n<p>2. Elijovisch F and Krakoff OR, “Captopril Associated With Granulocytopenia in Hypertension After Renal Transplant,” <i>Lancet</i>, 1980, 1(8174):927-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6103273\">[PubMed 6103273]</a></p>\n<p>3. Edwards CR, Drury P, Penketh A, et al, “Successful Reintroduction of Captopril Following Neutropenia,” <i>Lancet</i>, 1981, 1(8222):723. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6110936\">[PubMed 6110936]</a></p>\n<p>4. Gossmann J, Kachel HG, Schoeppe W, et al, “Anemia in Renal Transplant Recipients Caused by Concomitant Therapy with Azathioprine and Angiotensin-Converting Enzyme Inhibitors,” <i>Transplantation</i>, 1993, 56(3):585-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8212154\">[PubMed 8212154]</a></p>\n<p>5. Lin C, Datta V, Okwan-Duodu D, et al, “Angiotensin-Converting Enzyme is Required for Normal Myelopoiesis,” <i>FASEB J</i>, 2011, 25(4):1145-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21148418\">[PubMed 21148418]</a></p>\n<p>6. Vlahakos DV, Marathias KP, Madias NE, “The Role of the Renin-Angiotensin System in the Regulation of Erythropoiesis,” <i>Am J Kidney Dis</i>, 2010, 56(3):558-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20400218\">[PubMed 20400218]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2894":"<p><b>Title</b> Vitamin K Antagonists / AzaTHIOprine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> AzaTHIOprine may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of coumarin derivatives if azathioprine is initiated/dose increased, or increased effects if azathioprine is discontinued/dose decreased. An adjustment in warfarin dosage may be needed.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> A few case reports describe an increased requirement in warfarin or acenocoumarol dosage when patients were concurrently treated with azathioprine or mercaptopurine.<sup>1,2,3,4,5</sup> In one case warfarin requirements decreased to 5 mg/day within a few weeks of discontinuing azathioprine (14-17 mg/day while taking azathioprine).<sup>1</sup> Another case describes increased warfarin requirements during each cycle of mercaptopurine therapy.<sup>4</sup> The mechanism of these interactions is unknown. An animal study has demonstrated the potential for mercaptopurine to increase the synthesis or activation of prothrombin, thereby increasing coagulability in the absence of warfarin.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Singleton JD and Conyers L, “Warfarin and Azathioprine: An Important Drug Interaction,” <i>Am J Med</i>, 1992, 92(2):217-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1543209\">[PubMed 1543209]</a></p>\n<p>2. Rivier G, Khamashta MA, and Hughes GR, “Warfarin and Azathioprine: A Drug Interaction Does Exist,” <i>Amer J Med</i>, 1993, 95(3):342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8368235\">[PubMed 8368235]</a></p>\n<p>3. Spiers AS and Mibashan RS, “Increased Warfarin Requirement During Mercaptopurine Therapy: A New Drug Interaction,” <i>Lancet</i>, 1974, 2(7874):221-2 (letter). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4135641\">[PubMed 4135641]</a></p>\n<p>4. Martin LA and Mehta SD, “Diminished Anticoagulant Effects of Warfarin with Concomitant Mercaptopurine Therapy,” <i>Pharmacotherapy</i>, 2003, 23(2):260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12587816\">[PubMed 12587816]</a></p>\n<p>5. Fernandez MA, Regadera A, and Aznar J, “Acenocoumarol and 6-mercaptopurine: An Important Drug Interaction,” <i>Haematologica</i>, 1999, 84(7):664-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10406922\">[PubMed 10406922]</a></p>\n<p>6. Martini A and Jahnchen E, “Studies in Rats on the Mechanism By Which 6-Mercaptopurine Inhibits the Anticoagulant Effect of Warfarin,” <i>J Pharmacol Exp Ther</i>, 1977, 201(3):547-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=864594\">[PubMed 864594]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2896":"<p><b>Title</b> Theophylline Derivatives / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Macrolide Antibiotics may decrease the metabolism of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for toxic effects of theophylline derivatives if a macrolide antibiotic is initiated or the dose is increased. This is of most concern with erythromycin or troleandomycin. Consider using a noninteracting macrolide. Other macrolides appear to have little to no affect on theophylline.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Clarithromycin, Erythromycin (Systemic)<br><b>Exceptions</b> Azithromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin, Telithromycin</p>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline*, Theophylline*<br><b>Exception</b> Dyphylline</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Macrolide antibiotics exhibit varying effects on the disposition of theophylline derivatives, with troleandomycin and erythromycin exhibiting the greatest effects. With repeated dosing troleandomycin has been reported to decrease theophylline clearance as much as 50%.<sup>1,2</sup> Theophylline serum concentrations have been increased as much as 40% by concomitant therapy with erythromycin.<sup>3,4,5,6,7,8,9,10,11,12</sup> In contrast, some reports showed no effect of erythromycin.<sup>13,14</sup> A variety of factors (eg, erythromycin dose/duration) may have affected these results. Azithromycin and clarithromycin appear to have little to no effect on the disposition of theophylline derivatives.<sup>15,16,17,18,19,20</sup> The mechanism of this interaction is likely related to macrolide inhibition of CYP isoenzymes. In such case, clarithromycin would be expected to exhibit some effects. Telithromycin, a ketolide antibiotic, is reported to cause no changes in the pharmacokinetics of theophylline.<sup>21</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Weinberger M, Hudgel D, Spector S, et al, “Inhibition of Theophylline Clearance by Troleandomycin,” <i>J Allergy Clin Immunol</i>, 1977, 59(3):228-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=300083\">[PubMed 300083]</a></p>\n<p>2. Eitches RW, Rachelefsky GS, Katz RM, et al, “Methylprednisolone and Troleandomycin in Treatment of Steroid-Dependent Asthmatic Children,” <i>Am J Dis Child</i>, 1985, 139(3):264-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3872062\">[PubMed 3872062]</a></p>\n<p>3. Reisz G, Pingleton SK, Melethil S, et al, “The Effect of Erythromycin on Theophylline Pharmacokinetics in Chronic Bronchitis,” <i>Am Rev Resp Dis</i>, 1983, 127(5):581-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6846940\">[PubMed 6846940]</a></p>\n<p>4. Branigan TA, Robbins RA, Cady WJ, et al, “The Effects of Erythromycin on the Absorption and Disposition Kinetics of Theophylline,” <i>Eur J Clin Pharmacol</i>, 1981, 21(2):115-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7341279\">[PubMed 7341279]</a></p>\n<p>5. Zarowitz BJ, Szefler SJ, and Lasezkay GM, “Effect of Erythromycin Base on Theophylline Kinetics,” <i>Clin Pharmacol Ther</i>, 1981, 29(5):601-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7214790\">[PubMed 7214790]</a></p>\n<p>6. Cummins LH, Kozak PP, and Gillman SA, “Erythromycin’s Effects on Theophylline Blood Levels,” <i>Pediatrics</i>, 1977, 59:144.</p>\n<p>7. LaForce CF, Miller MF, and Chai H, “Effect of Erythromycin on Theophylline Clearance in Asthmatic Children,” <i>J Pediatr</i>, 1981, 99(1):153-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7252653\">[PubMed 7252653]</a></p>\n<p>8. Iliopoulou A, Aldhous ME, Johnston A, et al, “Pharmacokinetic Interaction Between Theophylline and Erythromycin,” <i>Br J Clin Pharmacol</i>, 1982, 14(4):495-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7138734\">[PubMed 7138734]</a></p>\n<p>9. Paulsen O, Hoglund P, Nilsson LG, et al, “The Interaction of Erythromycin With Theophylline,” <i>Eur J Clin Pharmacol</i>, 1987, 32(5):493-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3622597\">[PubMed 3622597]</a></p>\n<p>10. Cummins LH, Kozak PP Jr, and Gillman SA, “Theophylline Determinations,” <i>Ann Allergy</i>, 1976, 37(6):450-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=999063\">[PubMed 999063]</a></p>\n<p>11. May DC, Jarboe CH, Ellenburg DT, et al, “The Effects of Erythromycin on Theophylline Elimination in Normal Males,” <i>J Clin Pharmacol</i>, 1982, 22(2-3):125-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7068935\">[PubMed 7068935]</a></p>\n<p>12. Green JA and Clementi WA, “Decrease in Theophylline Clearance After the Administration of Erythromycin to a Patient With Obstructive Lung Disease,” <i>Drug Intell Clin Pharm</i>, 1983, 17(5):370-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6861626\">[PubMed 6861626]</a></p>\n<p>13. Pingleton SK, Kelly SJ, and Ryan PB, “The Lack of Influence of Erythromycin on Plasma Theophylline Serum Levels,” <i>Chest</i>, 1980, 78(2):352.</p>\n<p>14. Maddux M, Organek H, Hasegawa G, et al “Erythromycin Alteration of Theophylline Pharmacokinetics. Lack of Effect at Steady-State,” <i>Am Rev Resp Dis</i>, 1981, 123:60.</p>\n<p>15. Hopkins S, “Clinical Toleration and Safety of Azithromycin,” <i>Am J Med</i>, 1991, 91(Suppl 3A):40-5S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1656742\">[PubMed 1656742]</a></p>\n<p>16. Davies BI, Maesen FP, and Gubbelmans R, “Azithromycin (CP-62, 993) in Acute Exacerbations of Chronic Bronchitis: An Open, Clinical, Microbiological, and Pharmacokinetic Study,” <i>J Antimicrob Chemother</i>, 1989, 23(5):743-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2547747\">[PubMed 2547747]</a></p>\n<p>17. Coates PE, et al, “A Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Effect of Orally-Administered Azithromycin on the Plasma Concentration Profile of Theophylline,” Data on file, 1991, Pfizer Labs, Inc.</p>\n<p>18. Gilllum JG, Israel DS, Scott RB, et al, “Effect of Combination Therapy With Ciprofloxacin and Clarithromycin on Theophylline Pharmacokinetics in Healthy Volunteers,” <i>Antimicrob Agents Chemother</i>, 1996, 40(7):1715-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8807068\">[PubMed 8807068]</a></p>\n<p>19. Ruff F, Chu SY, Sonders RC, et al, “Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of Theophylline,” 30th Ann Intersci Conf, <i>J Antimicrob Chemother</i>, Atlanta, GA, October 23, 1990, 213.</p>\n<p>20. Valentino GR, Fabio C, and Guffanti EE, “Theophylline Interaction With New Quinolones and Macrolides in COPD Patients,” <i>Am Rev Resp Dis</i>, 1991, 143:A498.</p>\n<p>21. Ketec [package insert]. Laval, Quebec: Aventis Pharma Inc, 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","2899":"<p><b>Title</b> Loop Diuretics / Nonsteroidal Anti-Inflammatory Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of loop diuretics with concurrent use of a nonsteroidal anti-inflammatory agent (NSAID). Consider using an NSAID that holds a lesser potential for interacting with the loop diuretic (e.g., diflunisal, flurbiprofen, ketoprofen, and ketorolac). Patients with heart failure or cirrhosis may be more sensitive to alterations in fluid balance, in which case consideration should be given to avoiding the concomitant use of NSAIDs and loop diuretics. Patients should also be monitored closely for evidence of acute kidney injury (AKI) with this combination, particularly if also used together with an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blockers (ARB) as the use of such a three-drug combination may convey a particularly high risk for AKI. Bumetanide U.S. prescribing information and Canadian product monograph both specifically recommend avoiding concomitant use with indomethacin.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide*, Ethacrynic Acid, Furosemide*, Torsemide</p>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal*, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen*, Ibuprofen (Topical), Indomethacin*, Ketoprofen*, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen*, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic)*, Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> To varying degrees, based on the specific agents and possibly doses used, nonsteroidal anti-inflammatory agents (NSAIDs) may reduce the diuretic effects of loop diuretics. Urinary excretion of chloride, potassium, and sodium are also affected. The most significant effects appear to be caused by indomethacin, ibuprofen, lornoxicam, naproxen, and piroxicam.<sup>1,2,3,4,5</sup> Cases in patients with heart failure demonstrate the ability of ibuprofen, naproxen, and piroxicam to abolish the diuretic effects of furosemide during concomitant administration.<sup>6,7,8</sup> Lesser effects on furosemide-induced diuresis have been reported with flurbiprofen, diflunisal, ketoprofen, and ketorolac.<sup>1,9,10</sup> These agents might be reasonable alternatives to the higher impact agents noted above.<br><br>The findings of several case-control and cohort studies suggest that the risk for acute kidney injury (AKI) may be increased with concurrent use of an NSAID and a diuretic, and that the risk may be particularly high with use of the three drug combination of an angiotensin converting enzyme (ACE) inhibitor/angiotensin receptor blocker, diuretic, and NSAID,<sup>11,12,13,14</sup> and higher than that observed with any single drug or two drug combination.<br><br>Loop diuretics appear to mediate some of their therapeutic effects via increasing the concentrations of prostaglandins (possibly by stimulating prostaglandin synthesis) which subsequently increase renal blood flow. NSAIDs would block this activity and, thus, diminish the diuretic response.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Anonymous. Non-steroidal anti-inflammatory drugs and frusemide-induced diuresis. <i>Br Med J (Clin Res Ed)</i>. 1981;283(6297):988-989. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6793204\">[PubMed 6793204]</a></p>\n<p>2. Brater C, Chennavasin P. Indomethacin and the response to bumetanide. <i>Clin Pharmacol Ther</i>. 1980;27(3):421-425. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7357799\">[PubMed 7357799]</a></p>\n<p>3. Brater DC, Fox WR, Chennavasin P. Interaction studies with bumetanide and furosemide. Effects of probenecid and of indomethacin on response to bumetanide in man. <i>J Clin Pharmacol</i>. 1981;21(11-12 Pt 2):647-653. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7338575\">[PubMed 7338575]</a></p>\n<p>4. Kaufman J, Hamburger R, Matheson J, Flamenbaum W. Bumetanide-induced diuresis and natriuresis: effect of prostaglandin synthetase inhibition. <i>J Clin Pharmacol</i>. 1981;21(11-12 Pt 2):663-667. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6802882\">[PubMed 6802882]</a></p>\n<p>5. Hitoglou-Makedou A, Lawson M, Turner P, Ferber HP. Comparison of chlortenoxicam and indomethacin on frusemide-induced diuresis. <i>Postgrad Med J</i>. 1989;65(769):821-823. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2694142\">[PubMed 2694142]</a></p>\n<p>6. Laiwah AC, Mactier RA. Antagonistic effect of non-steroidal anti-inflammatory drugs on frusemide-induced diuresis in cardiac failure. <i>Br Med J (Clin Res Ed)</i>. 1981;283(6293):714. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6793136\">[PubMed 6793136]</a></p>\n<p>7. Goodenough GK, Lutz LJ. Hyponatremic hypervolemia caused by a drug--drug interaction mistaken for syndrome of inappropriate ADH. <i>J Am Geriatr Soc</i>. 1988;36(3):285-286. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3339238\">[PubMed 3339238]</a></p>\n<p>8. Baker DE. Piroxicam--furosemide drug interaction. <i>Drug Intell Clin Pharm</i>. 1988;22(6):505-506. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3396462\">[PubMed 3396462]</a></p>\n<p>9. Wa TC, Lawson M, Jackson SH, Hitoglou-Makedou A, Turner P. Interaction of ketoprofen and frusemide in man. <i>Postgrad Med J</i>. 1991;67(789):655-658. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1924052\">[PubMed 1924052]</a></p>\n<p>10. Toradol (ketorolac) [prescribing information]. Nutley, NJ: Roche Laboratories Inc.; March 2013.</p>\n<p>11. Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDS: “The Triple Whammy”. <i>Nefrologia</i>. 2015;35(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26300514\">[PubMed 26300514]</a></p>\n<p>12. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. <i>Kidney Int</i>. 2015;88(2):396-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25874600\">[PubMed 25874600]</a></p>\n<p>13. Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL; French Network of Regional Pharmacovigilance Centres. More on the “Triple Whammy”: antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database. <i>Ren Fail</i>. 2014;36(7):1166-1168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24826803\">[PubMed 24826803]</a></p>\n<p>14. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. <i>BMJ</i>. 2013;346:e8525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23299844\">[PubMed 23299844]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}